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9BACKGROUND 
Introduction 
This thesis investigates pregnancy rates after adolescent and adult onset cancer for both 
genders (paper I), birth outcomes in offspring born after cancer in either of the parents 
(paper II), and cause-specific survival of females diagnosed with cancer during pregnancy 
or lactation period and for women with a previous cancer diagnosis and with subsequent 
pregnancies (paper III). The most frequent cancer types in the age group 16-49 years at 
diagnosis are selected and analyses are performed with comparison to controls from the 
general population.
The growing number of cancer patients diagnosed in adolescence or in young adulthood,
together with the increasing prognosis for many cancer types, makes it necessary to 
investigate the different long-term effects of cancer and its treatment. Concerning fertility 
and birth outcomes, most studies have focused on childhood cancer, and there has been a
lack of studies based on large, unselected materials. Counselling young adult cancer patients 
about future fertility and the risk of adverse outcomes for the offspring is important, but 
large studies are needed to provide evidence-based advice. Further, counselling and care-
taking of females being diagnosed with cancer during pregnancy are challenging. Again, 
research is needed to give evidence-based advice. When the study started in 2006, there 
were few large studies covering more than one cancer type. Case-reports provide more 
detail, but the statistics from population-based studies are crucial in questions of incidence 
and for reliable estimates of prognosis.  
In 2005, a paper was published based on material from the Norwegian Radium Hospital, 
showing that fertility rates for former cancer patients were lower than among the general 
population, and that female cancer patients had lower fertility rates than male patients.1
Further, the authors found elevated risks of congenital anomalies among the offspring of 
male cancer survivors.2 There was a need for further investigation in a nationwide material.
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Cancer epidemiology 
For the Norwegian population during 2010, more than 27,000 individuals were diagnosed 
with a malignancy. The vast majority were aged over 50 years, but about 8% of the males 
and 14% of the females were between 15 and 49 years of age at diagnosis.3
 
 
 
Figure 1 
The most frequent incident cancer by age and gender, 2006-2010. Part of figure 5 from Cancer in 
Norway 2010.3 
 
 
Figure 1 shows the incidence of cancer and the most frequent cancer types in adolescence 
and young adulthood. The cancer incidence has, in general, been increasing, also in younger 
age groups (Figure 2), and one out of three individuals in Norway is expected to be 
diagnosed with cancer before age 75.3
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Figure 2 
Number of persons diagnosed with cancer at age 15-49 years in Norway per year during a period of 
three decades. Extracted from “Cancer in Norway” for the actual years.  
 
Cancer is the main disease-related cause of death for both genders in the age group 15-49 
years old.4 The prevalence, i.e. the number of survivors in the population who are alive and 
have been diagnosed with cancer, has increased over the last decades as the prognosis has 
improved for several cancer types (Table 1).
 
Table 1 
Prevalence of cancer, both genders, from The Cancer Registry of Norway 
Year Total no. of cancer 
survivors 
Years after diagnosis 
         <1                        1-4                        5-9                      10+ 
1980 71,880 10,526 24,460 16,589 20,305 
1990 103,659 12,796 31,130 23,862 35,871 
2000 143,410 16,063 43,009 32,073 52,265 
2010 207,224 20,237 60,778 48,717 77,492 
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Cancer survivorship 
The term “cancer survivor” was introduced in the literature during the 1980s.5 Cancer 
survivors were originally limited to individuals who had survived for five years or more 
after their diagnosis. Today, we often call them long-term survivors. The expression cancer 
survivor is nowadays often used for “someone who has had cancer”, and includes everyone 
once diagnosed with cancer who is alive, independent of the period of time since diagnosis. 
For this thesis, this recent definition will be used, and the terms cancer patient and cancer 
survivor will be used interchangeably. In contrast, there are examples in the literature of an 
extended use of the expression cancer survivor, including the cancer patient’s spouse and 
remaining family.6
The number of cancer survivors throughout the world has increased over the last few 
decades. By the end of 2010 there were more than 207,000 persons in Norway who had 
been previously diagnosed with cancer and were still alive. The majority (about 126,000) of 
those were diagnosed five years ago or more (Table 1). 
The research into cancer survivorship has increased during the last two decades. The topic 
covers all types of long-term adverse effects, both physical and psychosocial, caused by the 
cancer and its treatment. Mapping adverse effects and trying to give advice and generate 
guidelines are of high importance, both for the individuals who have experienced cancer and 
are trying to resume life again, and for their caregivers. Also, cost estimates of cancer 
survivorship care plans are a public health concern. Some guidelines have been published, 
but on the whole, except for follow-up care focusing on cancer recurrence, care plans for 
managing the long-term effects of cancer and its treatment are lacking.7;8
The National Resource Centre for Late Effects after Cancer Treatment at the cancer clinic at 
Rikshospitalet was established in 2005, initiated by the Norwegian Ministry of Health and 
Care Services to meet the needs of the increasing cancer survivor population, their care 
givers and the societies handling the special questions raised.9 The Resource Centre has 
published papers on a diversity of childhood and adult cancer survivorship topics, as 
specific treatment-related adverse effects, fertility, fatigue, impaired physical function, sick 
leave and work ability, increased morbidity, and second cancers.1;10-21
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Long-term effects of cancer and its treatment 
Most cancer treatments lead to adverse effects, often grouped into acute, late, and long-term 
sequelae.22 Acute effects are limited to the period of treatment and roughly one year 
afterwards, and longer lasting adverse effects are classified as long-term. Late adverse 
effects are those with a late debut, more than a year after treatment. Adverse effects are 
caused by the disease and the treatment. Individual factors, such as genetics and lifestyle, 
are of importance for the type and degree of sequelae. Sequelae such as cardiovascular 
disease or second cancer might be severe, or even life-threatening. 
Being diagnosed with a potentially life-threatening disease might have both physical and 
psychosocial consequences. The psychosocial consequences of cancer and/or its treatment 
might include depression, anxiety, sleep-disorders, fatigue, and fear of relapse. Both the 
physical and mental consequences of cancer can lead to difficulties in daily life, influencing 
physical ability, employment, income, family life, and social behaviour. 
There are effects caused by the cancer diagnosis and its treatment that are likely to influence 
the choice and ability of future parenthood. Morbidity like heart failure, reduced lung or 
kidney function, neurological problems, disabilities, or psychosocial factors, as mentioned 
above, might influence different parts of life, including fertility. For the remainder of this 
section, I will mainly focus on reduced fertility after cancer due to sequelae, not specifically 
categorised as acute or long-term sequelae, since both could be present. Morbidity which
secondarily is likely to influence fertility or family-building are not estimated in the 
analyses.  
In this thesis, reproduction after cancer is one of the main outcomes measured by comparing 
cancer survivors and age-matched controls without a history of cancer. Research has shown 
that at least some cancer survivors have reduced fertility.1;2;23;24 Additionally, female 
survivors of breast cancer or brain tumours have slightly lower marriage rates compared 
with their cancer-free counterparts,25 and survivors of testicular and cervical cancer tend to 
get divorced more often than the general population.26
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Cancer and fertility 
The term fertility is often defined as the actual number of children one has, while fecundity 
is the potential reproductive ability (to conceive and give birth to live children). Fertility, 
reproduction after cancer, and parenthood are used interchangeably in this thesis, meaning 
the number of conceptions leading to registered pregnancies, as a measure of the ability to 
conceive, with or without assisted reproductive technologies. Infertility is usually defined as 
not getting pregnant in spite of unprotected intercourse for one year or longer. For cancer 
survivors, one year might be too short a period, which will be further discussed below. 
Delay of childbearing to the late twenties or the early thirties has become usual in the 
western world in the last few decades. In Norway, the mean maternal age at first birth in 
1967 was 22.6 (SD 4.3), whereas forty years later it was 27.5 (SD 5.1).27 An increasing 
incidence of cancer combined with a delay of childbearing will necessitate the medical 
community’s increased awareness of problems related to cancer and fertility.
Both the cancer itself and the treatment might lead to subfertility or infertility, of temporary 
or permanent duration. Besides physical sequelae, cancer might have an influence on social 
and intimate relations.25 Cancer survivors might fear disease recurrence if getting pregnant, 
or fear of transferring cancer or other adverse conditions to the offspring28, which will 
interfere with family building after cancer. On the other hand, literature focusing on the 
psychosocial effects of cancer confirms the strong desire to have children, and the distress 
that infertility brings.28;29 Several initiatives to preserve fertility have been established 
during the last decades, to improve the post-treatment options for cancer survivors. This will 
be dealt with in this chapter, first with a closer look at male and female gametogenesis, 
cancer treatment effects, methods to avoid gonadotoxicity, and further about methods to 
preserve fertility if the treatment is potentially gonadotoxic.
Gametogenesis 
Spermatogenesis starts in puberty with the continuous production of mature sperm cells. 
The complete process lasts about 70 days with different phases, and more than 100 million 
sperm cells are produced every day.30 Primary germ cells formed in embryonic life undergo 
several divisions and finally become motile sperm cells. Spermatogenesis is regulated by 
luteinising hormone (LH) and follicle stimulating hormone (FSH) from the pituitary gland. 
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In the testicle, the germ cells are surrounded by Sertoli cells, which provide a protective 
matrix and nutrition for the germ cells, and Leydig cells, which produce testosterone 
following stimulation by LH. Testosterone is necessary for spermatogenesis; it gives 
feedback to the hypothalamus-pituitary axis, and is responsible for male body 
characteristics.  
A female foetus with gestational age of 20 weeks has 7-8 million oocytes in her ovaries. At 
birth, the number is about 1 million in each ovary, but at puberty, caused by apoptosis, this 
number will have decreased to about 400 000. At menopause, only 400-1000 follicles 
remain. In each menstrual cycle, usually only one oocyte is released by ovulation, but a 
dozen or more are consumed each month during this process. Ovarian atresia accelerates 
after the age of 35. As with spermatogenesis in males, the menstrual cycle and ovulation are 
stimulated by LH and FSH.31
Chemotherapy and fertility 
Cytotoxic drugs interfere in the cell division cycle, and rapidly dividing cells like germ cells 
are the most susceptible. The gonadotoxic risk profile caused by chemotherapy is described 
in Table 2. Most gonadotoxic agents threaten both male and female fertility. Alkylating 
agents (especially cyclophosphamide) and procarbazine are probably the agents with highest 
risk to cause infertility. The drugs induce an impairment of follicular maturation and a
depletion of primordial follicles in the ovaries. Alkylating agents also damage the steroid-
producing granulosa cells. In the testicles, both spermatogonia, Leydig cells and Sertoli cells 
are attacked, leading to disrupted spermatogenesis, but Leydig cells are less sensitive, and 
testosterone production is usually maintained.32 The level of gonadotoxicity caused by the 
cytostatic drugs is dependent on treatment type, combination, total dose, age at treatment 
(especially for females), and individual vulnerability, such as genetic factors and pre-
treatment reserve. Apart from risk classification (Table 2) and age at treatment, we are still 
unable to accurately predict using current diagnostic tools who will be more vulnerable to 
chemotherapy than others.
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Table 2.  
Gonadotoxic risks for female and male patients, risk assessment based on type (and dose) of 
treatment. Abbreviations are described in the footnote. 
 High risk Intermediate 
risk 
Low risk Unknown 
risk 
Chemotherapy, 
single agents 
Cyclophospahmide 
Busulfan 
Melphalan 
Chlorambucil 
Dacarbazine 
Procarbazine 
Ifosfamide 
Thiotepa 
ŝƐƉůĂƚŝŶшϱϬϬŵŐͬŵ2* 
Anthracyclines 
Cisplatin  
фϰϬϬŵŐͬŵ2* 
Carboplatin 
 
Methotrexate 
Bleomycin 
5-Fluouracil 
Actinomycin-D 
Vinca alkaloids 
Mercaptopurine 
Etoposide 
Fludarabine 
Taxanes 
Oxaliplatin 
Irinotecan 
Monoclonal 
antibodies 
Tyrosine 
kinase 
inhibitors 
Chemotherapy, 
combinations 
High-dose 
ĐǇĐůŽƉŚŽƐƉŚĂŵŝĚĞͬ 
busulfan and 
hematopoetic stem 
cell transplantation. 
BEACOPP, CMF, CAF, 
FEC x 6 in women > 
40 years 
CMF, CAF,  
FEC x 6 in women 
30-39 years. 
AC, EC x 4 in 
women > 40 years 
ABVD 
CMF, CAF,  
FEC x 6 in women 
<30 years. 
CHOP, CVP 
AC in women  
< 40 years 
 
Footnote: ABVD: doxorubicin (originally adriamycin), bleomycin, vinblastine, and dacarbazine; AC: 
doxorubicin and cyclophosphamide; BEACOPP: bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine, prednisolone; CAF: cyclophosphamide, doxorubicin, 
and 5-fluouracil: CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisolone; CMF: 
cyclophosphamide, methotrexate, and 5-fluouracil; CVP: cisplatin, vinblastine, and prednisolone; 
EC: epirubicin and cyclophosphamide; FEC: 5-fluouracil, epirubicin, and cyclophosphamide. 
*Cumulative doses. Adapted from 33;34 
Male spermatogenesis has the ability to recover, if stem cells have survived. Recovery is 
seen over a period of one to five years after gonadotoxic treatment for many male 
survivors.35;36 For females, gonadotoxic chemotherapy may reduce the total number of 
oocytes or accelerate the physiologic loss, leading to premature ovarian failure (POF, early 
menopause). Irreversible amenorrhoea, lasting more than 12 months and with raised FSH 
levels before the age of 40, is regarded as POF. Ovarian damage is dependent on the type of 
drug, total dose, and individual factors, especially age at the time of treatment. Risk of 
ovarian failure is highest among women closest to natural menopause, who have smaller 
follicular reserves. Even drugs classified as intermediate or low gonadotoxic treatment 
increase the risk of POF, even when normal menstrual cycles had been regained in the 
meantime.32
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For some cancer types, changes in chemotherapy during the last decades have offered less 
gonadotoxic chemotherapy. An example of this is the change from combinations containing 
procarbazine to ABVD for Hodgkin’s lymphoma patients, which has increased fertility after 
treatment in both genders.13;32;35;37
Radiotherapy and fertility 
Irradiation is a fertility threat if the reproductive organs are included in the field or hit by 
scattered irradiation (deviated rays from the straight beam). Besides the general effects 
which radiotherapy might cause, such as fibrosis and reduced vascularisation, the gonads 
themselves are sensitive to irradiation, and high doses imply infertility. Sperm 
concentrations usually reach a nadir 4-6 months after irradiation, and time to recovery is 
dose-dependent. It is reported that recovery to pre-irradiative sperm concentrations for a 
single dose of 1 Gy can be seen after 9-PRQWKVDQGWKDW*\WRWKHWHVWHVUHTXLUHV
years.38 Fractionated treatment tends to give longer recovery times than single-dose 
treatment. Temporary arrest of spermatogenesis with recovery within 12-30 months is 
reported after scattered irradiation from abdominal fields with total doses from 0.2-0.9
Gy.31;39 For females, scattered irradiation could result in ovarian dysfunction with doses 
<0.1 Gy to the ovaries, at least if the woman is above 40 years old. For younger females, the 
tolerance is higher, as total doses of  at least 4-6 Gy are needed to induce permanent ovarian 
failure.31 To limit irradiation of the gonads, lead shielding is used to avoid gonadotoxic 
doses. Oophoropexy, surgical removal of the ovaries outside the radiation field, is
sometimes used, but the vascularisation of the ovaries might be disturbed and the success 
rate is modest.40
A secondary fertility-decreasing effect may occur if the brain is irradiated, including the 
hypothalamus and the pituitary gland, which will influence the menstrual cycle or the 
stimulation of spermatogenesis, by disturbing the production of FSH and LH. 
For premenopausal breast cancer patients diagnosed prior to the 1980s, ovarian irradiation 
in absolute ovariotoxic doses (10-12 Gy) was used as an anti-hormonal treatment with a 
gradual substitution to tamoxifen during the 1980s.41;42
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Surgery and fertility 
Removing the reproductive organs by surgery, like bilateral orchiectomy in males and 
hysterectomy or bilateral oophorectomy in females, obviously leads to infertility. Unilateral 
oophorectomy or orchiectomy will preserve fertility, but the remaining fertility will be 
dependent on the functional status of the contralateral organ. Gynaecological cancers in 
premenopausal women stand in an exceptional position with regards to reduced fertility 
after cancer treatment. Action to preserve fertility has been taken since the 1970s, by 
offering conisation to selected patients with cervical cancer of stage Ia (microinvasive 
disease).43 Radical trachelectomy, which was introduced by Dargent and colleagues in the 
late 1980s, has been used as a fertility-preserving alternative since 1992. This method has
also been used for women with stage Ib1 tumours < 2 cm and without risk factors, in 
combination with pelvic lymphadenectomy.44;45 Furthermore, ovarian cancer patients with 
low stage disease have, since the 1980s, been given the option of unilateral oophorectomy,
eventually followed by hysterectomy and oophorectomy after giving birth to the desired 
number of children.45;46
Surgery close to the reproductive organs, like pelvic and retroperitoneal operations, might 
influence the vascular beds and disturb nerve functions, and thus influence sexual life 
(leading to sexual dysfunction), secondarily reducing fertility, or the capability to bear a 
pregnancy to term.47 Retroperitoneal lymph node dissection (RPLND) is an example of 
surgery leading to nerve dysfunction, which was used in Norway from the 1980s onwards in 
testicular cancer patients both for diagnostic and treatment purposes. During the first five 
years, bilateral RPLND was most frequently used, resulting in nerve damage and dry 
ejaculation. In the late 1980s, unilateral and nerve-sparing procedures were introduced to 
improve fertility preservation, resulting in a reduction of men with post-operative 
ejaculatory dysfunction from 90% to 10%.48;49 Also, brain surgery, involving the 
hypothalamus and the pituitary gland, will influence sperm production and the ovulation 
cycle negatively.
Cancer as a cause of decreased fertility  
It has been proposed that testicular cancer is linked to subfertility,50 and Hodgkin’s 
lymphoma has also been associated with decreased fertility evaluated at diagnosis.51
Hypospadia (a birth defect; abnormally placed urethra opening) and cryptorchidism (an 
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undescended testicle) are both associated with an increased risk of testicular cancer.52 It has 
been postulated that poor semen quality (low sperm count), hypospadia, cryptorchidism, and 
testicular cancer all are symptoms of one underlying entity, called testicular dysgenesis 
syndrome (TDS). This syndrome is linked to development of the gonads in foetal life.52 The 
SURGXFWLRQRIȕK&*E\VRPHKLVWRORJLFDOVXEW\SHVRI WHVWLFXODUFDQFHU LVDOVRUHJDUGHG WR
have a negative effect on semen quality. Patients diagnosed with testicular cancer, with or 
without TDS, are often reported to have impaired spermatogenesis at diagnosis, meaning 
that the remaining testicle could also be involved.50
In males with Hodgkin’s lymphoma, low sperm counts (oligospermia or azoospermia; few 
or no sperm cells in a semen sample) are reported prior to treatment for up to 70% of 
patients53;54 in some studies, while others did not find any large decline in semen quality.55
The mechanisms are not fully understood, but are hypothesised to be linked to immune-
mediated processes with the increased release of pro-inflammatory cytokines.55 A difference 
associated to stage has also been shown. Low sperm counts at diagnosis are most likely 
associated with advanced stage and the presence of systemic effects of the cancer (B-
symptoms; fever, night sweats, weight loss), in particular fever and night sweats.32;51;53
Nevertheless, the decreased fertility before treatment seems to be temporary, with recovery 
reported for most survivors.
Fertility-preserving options prior to treatment 
Semen cryopreservation 
The first sperm bank in Norway, St. Olavs Hospital in Trondheim, opened in 1980, and the 
second in 1994, at Rikshospitalet in Oslo. Today, there are sperm banks also in Tromsø, 
Porsgrunn, Haugesund, and Bergen. Any sample with living sperm cells is frozen, and post-
pubertal men up to the age of 55 are given this option nowadays. However, it is reported 
that a low proportion of cancer survivors, only 7% of testicular cancer patients with semen 
cryopreservation prior to treatment, are using their samples to conceive after their treatment, 
with a success rate of about 50%.11
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ART (Assisted reproductive technologies) 
Most ART procedures include hormonal hyperstimulation of the ovaries and harvesting of 
multiple oocytes. IVF, in vitro fertilisation, has been possible in Norway since 1989 and 
uses a number of motile sperm cells for the fertilisation of oocytes in a culture medium. IVF 
is performed mainly in the case of female factor subfertility and in cases of sperm donation 
(oocyte donation is not legalized in Norway).56 Intra-cytoplasmic sperm injection (ICSI, 
also called microinjection) has been used since 1995. One selected sperm cell is injected 
into the oocyte directly. This technique is frequently used today and always if there is male 
factor of subfertility. 
Embryo and oocyte cryopreservation 
Oocyte and embryo cryopreservation requires hormonal stimulation and therefore usually a 
delay in treatment of 2-6 weeks. A new method with hormonal stimulation starting 
independently of the cyclic phase is able to reduce the time before harvesting, and the 
methods might then become a more realistic possibility for preserving fertility in cancer 
patients.57 Oocytes are harvested during ovulation, and IVF is performed in the case of 
embryo storage. In Norway, embryo cryopreservation requires a partner (marriage or 
cohabitate relation for at least two years). Oocyte cryopreservation is a possibility for single 
women, but oocytes are less robust to the freezing process than embryos, and the method is 
still considered experimental. Few women with cancer worldwide and in Norway have used 
embryo or oocyte cryopreservation.58
Ovarian tissue cryopreservation  
For females needing high gonadotoxic chemotherapy or abdominal-pelvic irradiation which
includes the ovaries, ovarian tissue cryopreservation might be the only option to preserve 
the possibility of getting pregnant after cancer. The technique is still considered 
experimental, but has been allowed in Norway since 2004. About 130 females have used 
this opportunity (as of ultimo 2012) and two autotransplantations have been performed in 
Norway (Tom Tanbo, personal communication). There is no lower age limit, and the 
method is the only possibility for pre-pubertal girls. The upper age limit for harvesting is 35 
years. Storage time is unlimited, but autotransplantation should optimally be performed 
before the age of 40, and the woman should have been cancer-free for at least 5 years. If a 
spontaneous pregnancy is not achieved in a set number months, hormonal stimulation is 
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employed to induce ovulation.59 By now, approximately 20 children have been born by 
means of this technique worldwide.60
Measuring post-treatment fertility potential 
Both male and female survivors might have apparent infertility for a period after treatment. 
Additionally, to minimise the risk of birth defects and other complications, the general 
advice to survivors who want to get pregnant after cancer is to delay conception for at least 
a year after the treatment has ended. The possible temporary sub- or infertility might last for 
some years. 
Today, we have several techniques available to estimate fertility potential. For males, sperm 
samples will show whether the concentration, morphology and motility are sufficient to 
fertilise an oocyte. A temporary subfertility or even infertility is described initially, and the 
recovery of sperm quality is seen during the first two-three years after treatment, classified 
as medium or even high gonadotoxic risk chemotherapy (Table 2).10;33;61 Furthermore,
hormones (FSH, LH, SHBG, and testosterone) regulating sperm production need to be 
evaluated. Elevated FSH might represent exocrine hypogonadism, and low testosterone 
and/or elevated LH could represent endocrine hypogonadism.  
For females, regular menses are not necessarily reliable evidence of preserved or regained 
fertility, as anovulatory cycles are possible. Oocyte reserves can be measured with 
ultrasound, assessing the number of antral follicles and the volume of the ovaries. Further, 
serum levels of different hormones are measured (FSH, LH, E2 (oestradiol), anti-Müllerian 
hormone (AMH), and inhibin B); the hormonal levels will indicate whether the woman has 
signs of gonadal dysfunction or is threatened by premature ovarian failure and early 
menopause. AMH is considered to be independent of the menstrual cycle (in contrast to the 
other hormones listed above), and reflects the number of follicles in the gonads.61 In healthy 
women, AMH values decrease with increasing age, which is further accelerated after 
gonadotoxic treatment. AMH might also be used as a pre-treatment prediction of fertility, 
but this is still experimental.
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Pregnancy after adolescent and adult cancer  
For young adult and adolescent cancer patients, facing a future without children might 
represent an extra burden and have a negative influence on quality of life. Fertility-
preserving attempts have been included in the guidelines for several cancer types, as 
described earlier for gynaecological cancer of low stage45 and Hodgkin’s lymphoma.62
However, for other malignant diagnoses, like acute leukaemia, more intensive treatment and 
highly gonadotoxic chemotherapy is required to cure the cancer, which unfortunately also is 
a real threat to their fertility.63;64
Surveys show that many young adult cancer survivors want to have children after cancer, 
but they are concerned about a pregnancy’s influence on their own health and about the 
cancer treatment’s influence on the offspring’s health.10;13;28;29 In the past, poor prognosis 
might have led to low fertility rates after cancer, for example in those diagnosed with 
leukaemia. Most studies report lower fertility-rates among cancer survivors than among 
controls.2;65-67 Besides, for female survivors, historic counselling often recommended either 
no future pregnancies, or at least a longer recurrence-free period (at least five years) before 
attempting pregnancy.  
The literature at the onset of this thesis consisted mainly of studies about spermatogenesis or 
amenorrhoea after cancer treatment,53 and about fertility after cancer in childhood or 
adolescence.68 Regarding parenthood in adult cancer survivors, a single-institution study 
from The Norwegian Radium Hospital showed a 10-year cumulative probability of having a
child after cancer in 14% in cancer survivors aged 15-45 years at diagnosis.1 Further, for 
selected cancer types, like testicular cancer, Brydøy et al. reported an overall paternity rate 
of 71% during the first 15 years after cancer diagnosis, with a range from 48-92% in the 
high-dose chemotherapy group compared to the surveillance group.10
Birth outcomes in the offspring of cancer survivors 
Several studies have been published assessing the risk of adverse birth outcomes among 
childhood cancer survivors.69-71 For this topic, case-reports and mono-institutional studies 
are more frequent than population-based studies, with the risk of selection bias. The main 
factors analysed are low birth weight, preterm birth, perinatal death and congenital 
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anomalies; other parameters have also been assessed, such as sex ratio, and factors 
associated with maternal health, all of which might influence foetal development and 
wellbeing. 
Congenital anomalies 
Major congenital anomalies occur in 3-4% of all pregnancies in the general population.27;56
Congenital anomalies are of different severity, and not all are detected during the first 
examinations of the newborn, which are those registered in the MBRN. When taking into 
account those birth defects presenting later in life, the incidence is at least twice these 
figures. The most vulnerable time in pregnancy is during organogenesis (the period when all 
organs are developed), i.e. the first 8 weeks after conception. 
Chemotherapy might have teratogenic effects and increase the risk of foetal death, 
abortions, and major malformations, if given during pregnancy, and especially in the first 
trimester.72 Both patients and health workers have been worried about whether pregnancy 
after cancer is associated with increased health risks for the offspring. However, reassuring 
results regarding chromosomal abnormalities among the offspring of childhood cancer 
survivors in comparison to cancer-free siblings and their offspring can be found in a 
population-based Danish study.73
A Norwegian mono-institutional study found a higher risk of fathering a child with 
malformations among selected male survivors, compared to controls, for all cancer types 
combined. The increased risk was only seen in the first child fathered by the survivors after 
cancer, and no such risk was observed among offspring of female survivors.2 Three Danish 
studies covering female survivors of breast cancer, malignant melanoma, and Hodgkin’s 
lymphoma did not find an increased risk of congenital anomalies among the offspring.74-76
A Swedish study covering breast cancer, which found contrasting results to those of the 
Danish study, observed a higher incidence of congenital anomalies among the offspring of 
survivors compared to their controls, and with a time trend pointing to an increased risk of 
the most recent period.77
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Perinatal death 
Stillbirth and infant mortality, often described as perinatal death, is one of the most severe 
adverse pregnancy outcomes, together with major malformations. Perinatal death has 
different definitions in the literature. Stillbirth is defined as the death of a foetus with a 
reasonable chance of survival outside the uterus, usually from the 28th gestational week. In 
this thesis, the cut off is set at 22 weeks, which is more frequently used nowadays.56 Further, 
a birth weight criterion of at least 500 g is added. The limits are given to exclude early 
stillbirths, where the underreporting might bias the analysis. Perinatal death includes the 
period before and during the delivery, and the first 7 days after delivery. The rates of 
perinatal mortality in the general population are low in Norway and Nordic countries. The 
rate of perinatal mortality has declined from 23.3/1000 births in 1967 to 5.8/1000 births in 
2006.27 The risk of perinatal death is, in general, increased with advanced maternal age, 
multiparity, maternal complications during pregnancy, maternal smoking, and obesity. 
For offspring of cancer survivors diagnosed during adolescence and adulthood, no increased 
risk of perinatal death is reported from larger studies,75-77 except for the first-borns of female 
cancer survivors who were childless at diagnosis (all cancer types seen together).2
Other adverse pregnancy outcomes 
Birth weight is linked to gestational age, and is a difficult outcome to measure. The 
condition that should be measured is intrauterine growth retardation, which is usually 
measured either by assessing small for gestational age or by dichotomising low birth weight 
/%:DWWHUPJDWZHHNVRIJHVWDWLRQ56 LBW at term has been reported from 
several studies about birth outcome in adult female cancer survivors.2;77;78
Preterm birth or prematurity is associated with higher risks of perinatal death, since the 
development for extra-uterine life not is fulfilled. Preterm birth for cancer survivors might 
be caused by a dysfunctional cervix or insufficient development of the placenta. An 
increased risk of preterm birth is reported for female cancer survivors who were pregnant 
after cancer.2;78;79
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Survival in females with pregnancy-associated cancer  
Approximately 1 per 1000 pregnant women will be diagnosed with cancer during 
pregnancy.80;81 The expression pregnancy-associated cancer is commonly used for breast 
cancer (see below), but also for other cancer types detected during pregnancy, or the first 
period after, usually the first year post-partum. The following paragraphs will deal with 
cancer diagnosed during or shortly after pregnancy, and the effect of subsequent 
pregnancies on cancer survival.
Pregnancy-associated cancer is a challenging situation for all involved, not only for the 
woman, her partner and their extended family, but also for health workers. Diagnostic 
procedures and treatment might harm the foetus, and making exceptions from the standard 
diagnostic and treatment procedures might be a threat to the mother’s health and prognosis, 
resulting in a delay in diagnosis and/or suboptimal treatment. A multi-disciplinary approach 
is necessary to optimise the situation for the mother and the unborn child.82 In general, 
surgery is preferably performed during the second trimester if possible. Most 
chemotherapeutic agents can be given during the second and third trimester, even though 
most cytotoxic have low molecular weight, which cross the placenta and reach the foetus 
(antimetabolites are the most teratogenic agents and should probably be avoided). 
Abdominal shielding should be used when radiotherapy is given during pregnancy, and 
irradiation involving the abdomen and pelvis should be delayed until after delivery. For 
females diagnosed with cancer after delivery, there are no reasons for treatment delay, but 
there is an indication for weaning from breastfeeding in the case of chemotherapy. 
The influence of pregnancy on cancer survival has long been a controversial issue, and has 
influenced the thinking and handling of cancer types like breast, ovarian, and endometrial 
cancer. Pregnancy implies physiological changes in endocrine and immunological systems. 
It has been hypothesised that increasing oestrogen (and progesterone) levels leads to rapid 
tumour growth and advanced disease with decreased survival.82 Pregnancy and lactation 
change the mammary glands, and permanent changes in hormone levels after childbearing 
are reported. The immunological system is down-regulated during pregnancy, to avoid 
rejection of the foetus. What these changes during pregnancy mean for the development of a 
malignant tumour and its course is still unknown.
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Breast cancer 
Breast cancer is the most common malignancy in women. The majority of women are 
diagnosed after menopause, but 5-10% is diagnosed before the age of 40.3;83 Pregnancy-
associated breast cancer (PABC) or gestational breast cancer (GBC) are common 
expressions in the literature, often including the first year post-partum. The reason why 
these expressions not only include pregnancy but also a period after, is that the tumour has 
developed during the pregnancy or even before, and has been exposed to the physiological 
changes caused by the pregnancy and the lactation period. The incidence of PABC is about 
2% of all cases diagnosed with breast cancer, or 1 in 3,000 to 1 in 10,000 pregnancies.84;85
Historically, women with breast cancer diagnosed during pregnancy or lactation were 
classified as inoperable.86 Breast cancer in young persons (below 30) was looked upon as 
very aggressive and with a poor prognosis, and this poor prognosis was further enhanced 
because of the hormonal stimulation and active metabolism during pregnancy and lactation. 
However, not all surgeons agreed with this view, but the notion that pregnancy termination 
was necessary to improve the prognosis was widespread. Basically, only those who 
terminated their pregnancy underwent mastectomy. With regard to subsequent pregnancies, 
it was considered safe if the patient had been radically treated.87 Later on, a survey was 
conducted in the 1950s, where 55 physicians especially interested in breast cancer were 
invited to participate. The majority agreed that breast cancer diagnosed during pregnancy 
should not alone lead to renouncement from surgical treatment. Subsequent pregnancies 
should be avoided, but sterilisation was not necessary. The surgeons were concerned that 
residual tumour cells would be stimulated by a subsequent pregnancy, leading to disease in 
the remaining breast or to metastases. Regarding the termination of pregnancy, there were 
disagreements; some believed that termination would improve the prognosis, and suggested 
termination even in the third trimester, while a smaller group thought that termination was 
not favourable for the prognosis.88
In the 1970s, when the prognosis of breast cancer in general had improved, the attitudes 
towards PABC changed, and localised breast cancer during pregnancy was principally 
viewed as operable.89 Primarily, women with node negative disease were advised to delay a 
subsequent pregnancy for at least three years after diagnosis. However, many pre-
menopausal women with oestrogen receptor-positive (ER+) disease underwent castration by 
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surgery or irradiation to eliminate the influence of ovarian oestrogen. In Norway, breast 
cancer patients underwent castration up to the early 1980s.42;90
Several studies up to the 1990s found a poor outcome for women diagnosed during 
pregnancy.91;92 Hypotheses regarding the observed aggressive outcome of PABC included 
explanations like hormonal changes, increased vascularisation, and other changes of the 
breast tissue which might enhance tumour growth..93;94 Oestrogens are in general known to 
induce breast tissue growth.91;92;95 In recent years, several publications have concluded that 
gestational breast cancer often is diagnosed in advanced stages. However, if stage is 
adjusted for, the prognosis is similar to females who were not pregnant when diagnosed.96
The breasts in pregnant and lactating women are difficult to examine, both clinically, with 
ultrasonography, or with mammography. A lump might thus be masked by  the overall 
firmness of the breast tissue, delaying the final diagnosis.82 The incidence of PABC is 
described as lower than expected, but higher after pregnancy than during pregnancy, 
pointing to a possible diagnostic delay.97;98
Regarding pregnancies subsequent to breast cancer, Sankila et al. described the favourable 
survival for women having babies after breast cancer using an expression borrowed from 
cancer and work life, namely the “healthy mother effect”.99 It underlines the selection of 
women who are cured of cancer and perceived healthy enough to initiate a pregnancy after 
their malignant diagnosis. The optimal time period between cancer diagnosis and a 
subsequent pregnancy is not fully investigated, and guidelines today are mostly based upon 
“common sense”, recommending waiting 2-3 years after diagnosis. An Australian group 
found improved overall survival in women who conceived at least 24 months after diagnosis 
(HR = 0.48, 95% CI 0.27 to 0.83).67 Similar figures were seen in a Danish study.65;100 Since 
a dual effect of pregnancy is seen on the lifetime risk of being diagnosed with breast cancer, 
with an initial increased incidence risk turning into a long-term decreased risk, it is crucial
to give advice regarding how long to delay pregnancy after cancer.101;102
Malignant melanoma  
The incidence of malignant melanoma has been increasing for the last few decades. A new 
diagnosis of malignant melanoma complicates 0.1–2.8 per 1000 pregnancies. Of all 
gestational cancers, malignant melanoma is reported to account for 8% to 30%, thus being
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one of the most common malignancies during pregnancy.82 The numbers seem to vary 
geographically and also with skin type, with a higher incidence among the fair-skinned 
population in the world.
In 1951, Pack and Scharnagel published a paper presumably reflecting common notions of 
malignant melanoma diagnosed in association with a pregnancy at the time. They described 
32 patients with pregnancy-associated malignant melanomas, and reported worse prognosis 
than expected for pregnant women.103 There was no comparison group with non-pregnant 
women at the time of diagnosis; also, upon closer inspection, only 10 were actually pregnant 
when diagnosed. It is also unclear whether the pregnant women were offered the same 
treatment as non-pregnant women. Still, this publication may have been the main reason 
why doctors have regarded malignant melanoma during pregnancy as a prognostic negative 
factor for decades.
There have been several hypotheses regarding malignant melanoma and pregnancy; Katz et 
al. have listed the most common ones.104 The notion that benign nevi may grow or change 
during pregnancy has been shown not to hold true. Regarding endogenous hormones and 
their possible influence on the risk of malignant melanoma, no association between ever 
having been pregnant and malignant melanoma risk is found.105 Furthermore, higher parity 
(more than five) seems to be protective against developing malignant melanoma, but if this 
is related to parity, hormonal factors, or behaviour, are unclear.106 Regarding exogenous 
hormones, oestrogen-containing oral contraceptives and hormonal replacement therapy have 
not been found to have any adverse effect with a greater risk of recurrence,107-110 and are not 
contraindicated for women with a history of localised malignant melanoma.111
Tamoxifen has been used as a single agent or in combination with chemotherapy in the 
treatment of disseminated malignant melanoma. The medicine has been described as 
inducing apoptosis and inhibiting angiogenesis, through which tumour cell growth was 
suppressed.112 However, meta-analyses have shown that Tamoxifen do not improve 
response or survival rates in malignant melanoma patients.112-114 The rationale for 
introducing Tamoxifen in the treatment of melanoma was originally driven by a hormonal 
hypothesis, because of the observed oestrogen receptors in the tumour cells and studies 
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reporting oral contraceptives leading to progression. More recent immunohistochemical 
techniques have failed to prove the existence of oestrogen receptors.112
Regarding malignant melanoma diagnosed during pregnancy, recent population-based 
studies do not confirm the “hormonal hypothesis” related to malignant melanoma, nor the 
finding of worse survival for women diagnosed during pregnancy.115-117 Initial tumour
thickness seems to be the only important prognostic factor, possibly besides tumour
site.110;115 Treatment of early stage disease involves only localised surgery, and there is no 
reason for the postponement of such treatment during pregnancy. 
Cervical cancer 
Cervical cancer is the most common gynaecologic malignancy associated with pregnancy, 
with an incidence of 1 in 1000 to 1 in 10,000 pregnancies.82;118 The symptoms are usually 
discharge, occasional bleeding or post-coital bleeding, which could be confusing during 
pregnancy. Until the 1980s, pregnancy termination was suggested for females diagnosed 
during their first or second trimester.119 In recent years, for females with early stage disease 
and no nodal involvement, pregnancy preservation is the aim. Vaginal examination with 
histological proof is necessary, while endocervical curettage is contraindicated. Complete 
excision by conisation might be performed by experienced teams during early pregnancy if 
invasive disease is suspected. The risks with conisation are bleeding, premature delivery, 
infection, and pregnancy loss. In cases where the cancer is detected at a later stage in the 
pregnancy, foetal maturity must be optimised followed by a planned early delivery and then 
cancer treatment.82;118 Delay of treatment for stage I disease to allow foetal maturation is 
found to be safe, when followed by frequent examinations to detect eventual progression. 
Caesarean section is recommended to prevent recurrences in the episiotomy scar, and 
vaginal delivery is, in some studies, listed as a prognostic negative factor for 
recurrence.120;121
The prognosis for women with cervical cancer during pregnancy is equal to non-pregnant 
women with similar stage.121-124 For females diagnosed with cervical cancer shortly after 
pregnancy, survival was found to be worse than for pregnant females with cervical cancer, 
and for controls who were not pregnant at the time of diagnosis. The two main risk factors 
were high stage and vaginal delivery.120
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Ovarian cancer  
The incidence of ovarian tumours during pregnancy is reported to be about 1-4%, but the 
majority of these are masses of benign character. The average estimated incidence of 
malignant ovarian tumours in pregnancy is approximately 1 in 10,000 to 1 in 20,000 
deliveries.82;125 Also, the view regarding ovarian cancer associated with pregnancy has been 
influenced by a hormonal hypothesis, and historically, this might have led to reluctance 
regarding treatment. Epidemiologic evidence shows that the risk of ovarian cancer is 
decreased following childbirth and oral contraceptives also have a protective effect.126 An 
ovarian tumour might be asymptomatic for a long period, but may become symptomatic 
during pregnancy when the uterus is enlarging, or may also represent a physical obstacle in 
the pelvis during delivery. The tumour might even be occasionally observed at the 
gestational routine ultrasonographic examination or during caesarean section, 125;127
Contrary to late diagnosis and poor prognosis, both of which are associated with ovarian 
cancer in general, pregnancy might in some cases lead to an early diagnosis. Diagnostics are 
mainly based on ultrasonography and clinical findings. The concentration of the ovarian 
cancer antigen 125 (CA-125) is described as higher than normal during the first trimester 
and postpartum, and can be misleading as a tumour marker in case of the detection of an 
ovarian mass.128 Pelvic CT is contraindicated during pregnancy. Surgical intervention is 
indicated for persistent adnexal masses suspected as malignant, preferably during the second 
trimester. 
Survival outcomes of pregnancy-associated ovarian cancer are not reported to be different 
from those among non-pregnant patients.127;129;130 Treatment approach depends on tumour
size, histological type, morphology, malignant potential, and term of pregnancy. 
Lymphoma and leukaemia 
The diagnosis of malignant lymphoma is reported to complicate 1 in 6000 pregnancies, 
mainly Hodgkin’s lymphoma (HL), as non-Hodgkin lymphoma (NHL) during pregnancy is 
very seldom reported.131 Leukaemia is reported to occur in about 1 of 75,000-100,000
pregnancies.81;82;132 The early incidence peak of HL is between 20 and 40 years of age, 
coincidentally with the childbearing years, while the mean age at diagnosis of NHL is 42. 
The influence of pregnancy on the course of HL has been controversial. In the 1950s, a 
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report concluded that survival was poorer for females diagnosed with HL during 
pregnancy.133 However, from the 1960s onwards, several series concluded that survival was 
similar for pregnant and non-pregnant females with HL, and that therapeutic abortion did 
not improve the course or survival.134-136 If diagnosed during pregnancy, the treatment of 
HL of low stage and indolent NHL might be safely delayed until after delivery, or at least 
until the second trimester.131;137-139
In the case of acute leukaemia, and aggressive NHL types, treatment must be started 
immediately, irrespective of gestational stage. The treatment represents a threat to the 
foetus, with a risk of miscarriage, intrauterine growth retardation, prematurity, and foetal 
death, but a delay will challenge maternal prognosis.140 Case-reports have only been
published about NHL139;141;142 and leukaemia during pregnancy; for NHL, 103 cases were 
reported in 1994 over a period of 60 years,143 and an additional 35 cases were reported by 
2005.137 Early diagnosis and proper treatment are necessary to obtain survival, as in non-
pregnant patients. Termination of pregnancy is recommended for females diagnosed in the 
first trimester, since evidence regarding intensive combination treatment for NHL or 
leukaemia is limited. Termination is not indicated for maternal benefit if diagnosed at a later 
gestational stage. If acute leukaemia is diagnosed during the first trimester, termination of 
pregnancy is usually required, especially in the case of stem-cell transplantation, which is 
contraindicated during pregnancy. Standard multi-agent chemotherapy is associated with 
foetal growth restriction and myelosuppression. However, several case-reports refer to no 
foetal toxicity or other adverse birth outcomes.131;137;144;145 There are reports of the 
successful modification of treatment with the exchange of dexamethasone to prednisone or 
methylprednisone because of foetal risk of neurologic sequelae, and exchange of 
methotrexate to arabinosylcytosine because of concerns over the potential toxic effect of 
methotrexate to trophoblastic cells.137
No association has been found between the incidence of NHL or leukaemia and pregnancy 
factors.146-148 The literature of subsequent pregnancies is scarce, and again, based on case-
reports.
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Brain tumours  
The term “brain tumours” represents a diverse classification, as intracranial tumours of all 
histological types, from benign lipomas to aggressive malignancies like glioblastomas, are 
included. The malignant potential is dependent on the type of tumour, its location, its size 
and its state of development. The literature about brain tumours occurring during pregnancy 
and the lactation period is scarce, and made up of case-reports; incidence rates are variable, 
but a Spanish study reported numbers of about 5 malignant cases per 100,000 pregnancies 
and a German study reported 3.6 per 100,000.149-152 As for other malignancies, there is a risk 
of diagnostic delay because the symptoms may be considered part of the common 
pregnancy conditions. Recent studies report no association between brain tumours and 
pregnancy,153;154 while some older studies point to an increased risk of meningioma for 
those ever pregnant155;156 Historically, hypotheses about hormonal changes causing an 
acceleration of growth during pregnancy were stated, and oestrogen and progesterone 
receptors are detected in brain tumours. The observation of enlarging meningiomas and 
neurinomas during pregnancy has often been explained by water retention and increased 
fluid content, supporting the observations of symptom onset during pregnancy and recovery 
after delivery.155;156 In contrast to older reports, Haas et al. reported fewer than expected 
number of intracranial malignancies during pregnancy compared to the general 
population.152 To my knowledge, survival rates have not been calculated for brain tumours 
in pregnant women compared to those of the non-pregnant population.
Hormonal changes after treatment are common, since the pituitary gland and hypothalamus 
are often involved in the brain tumour itself or its treatment. This means that fertility can be 
impaired, hormones of importance during pregnancy can be imbalanced, and the tumour
itself could also have caused fertility problems prior to diagnosis. Outcomes for subsequent 
pregnancies are scarcely reported.
Thyroid cancer 
The incidence rate of thyroid cancer during pregnancy ranges from 3 to 14 per 100,000 live 
births.82;157 Thyroid cancer is the most common endocrine tumour in young females in the 
general population. When diagnosed at a young age, the cancer usually has a non-aggressive 
histology related to a favourable prognosis. Females diagnosed during pregnancy have the 
same prognosis as non-pregnant patients, even though thyroid cancer during pregnancy may 
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grow faster since hormonal factors (hCG) could accelerate tumour progression, or maybe 
because of pregnancy-related immune tolerance.157;158 In a normal pregnancy, hCG 
stimulates the thyroid gland and increases its volume and its hormone production. For the 
above-mentioned reasons, diagnostic delay of gestational thyroid cancer is likely, and more 
advanced stages are often seen in pregnant women compared to non-pregnant women.82
Besides the challenge of handling thyroid cancer during pregnancy, the second challenge 
regarding this disease is to reach an adequate hormonal balance in the pregnant survivors 
after thyroid cancer using thyroxin substitution. Maternal supply of thyroid hormones is 
crucial for the normal development of the foetal brain, especially during the first trimester. 
Severe neurological disorder, miscarriage or foetal death can be the result of maternal 
hypothyroidism.82
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STUDY AIMS   
The principal aims of this project were to study the impact of cancer on fertility and on 
pregnancy outcomes after cancer in a population-based material. We also wanted to 
compare survival in females who had subsequent pregnancies or were diagnosed with 
cancer during pregnancy or the lactation period with survival in females without pregnancy-
associated cancer. We wanted to validate findings from the previous literature regarding 
these subjects. Based on the literature described in the introduction chapter, there is a lack of 
large, unselected, controlled materials investigating the following questions, and the 
findings are contradictory for several of the outcomes. The growing incidence of cancer 
among adolescents and young adults and of cancer during pregnancy emphasises the need of 
evidence-based knowledge, as far as such can be reached. 
In detail, the following research questions were defined:  
x Are pregnancy rates after cancer lower than in the general population?
x Are there differences in pregnancy rates regarding cancer type and 
treatment?
x Do male cancer survivors have higher fertility rates than female survivors?
x Have fertility-preserving cancer treatments resulted in increased fertility-
rates after cancer for selected cancer types?
x Are congenital anomaly rates in offspring of male cancer survivors higher 
than those in the general population?
x Are adverse pregnancy outcomes like perinatal death, preterm birth and low 
birth weight more frequently seen in infants delivered by female cancer 
survivors than in offspring of females without a previous cancer diagnosis?
x What is the incidence of pregnancy-associated cancer?
x Is survival for females diagnosed with a pregnancy-associated cancer poorer 
than for non-pregnant or non-lactating females with cancer, assessed for all 
and for selected cancer types? 
x Do female survivors with subsequent pregnancies have poorer survival than 
those not becoming pregnant after cancer?
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MATERIALS AND METHODS 
Data sources 
This is a population-based study with material from different national data sources. The 
Cancer Registry and the Medical Birth Registry of Norway were the main data sources for 
identifying cases and for outcome and explanatory variables. 
From 1964, all citizens in Norway have been given a unique personal identification number 
with 11 digits. It is called the birth number, and is composed of the date of birth, a three 
digit individual number, and two check digits. Since the 1960s, all inhabitants have been 
given such an identification number shortly after birth. This number enables personal 
information from different sources to be linked.
Cancer Registry of Norway (CRN) 
The CRN provides close to complete incidence data on all individuals diagnosed with 
cancer in Norway since 1953.159 The reporting is mandatory, initiated by a directive from 
the Ministry of Health and Social Affairs in 1951. The reporting is based on pathology and 
cytology reports, clinical records, and death certificates. Variables like cancer site, date of 
diagnosis, histological type, basis for the diagnosis, stage or extent of the disease, and initial 
treatment in broad terms (for the first four months) are reported.
Within the CRN, extent of disease is described as localised, regional spread, distant spread 
or unknown for most solid cancer types. Cervical cancer is categorised as stage of disease 
from I-IV, according to the Federation Internationale de Gynecologie et d’Obstetrique 
(FIGO). Similarly, breast cancer is classified as localised tumours (I), regional lymph node 
metastases (II), direct tumour extension to the chest wall or skin (III), or distant metastases 
(IV). Brain tumours include all benign and malignant intracerebral tumours and are not 
classified by stage or extent, nor is the extent of disease recorded for non-solid tumours like 
lymphoma and leukaemia. Treatment is notified with information on received or planned 
surgery, chemotherapy, radiotherapy, or endocrine therapy, or a combination of these 
modalities. More details, such as type of chemotherapy or target field or dose of 
radiotherapy are not registered. 
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Medical Birth Registry of Norway (MBRN) 
The MBRN was established in 1967, and is part of the Norwegian Institute of Public Health. 
Mandatory reporting from doctors or midwives attending the delivery and through antenatal 
health care visits ensures that all pregnancies in the country with a duration of at least 16 
weeks (since 2002, from 12 weeks) are registered. The MBRN collects data on maternal 
health before and during pregnancy and demographic data about the parents, based on 
standardised notification forms from the antenatal health care visits and the maternity ward. 
Gestational duration, complications during pregnancy and delivery, pregnancy outcome 
including date of birth, anthropometric measurements, and vital status of the newborn, and 
eventual diagnoses made during the initial stay on the maternity ward are all notified. 
Initiation of pregnancy by ART has been registered since 1988, as IVF, ICSI, or technique 
not notified. Unsuccessful attempts to conceive using ART and adoptions are not registered.
Induced abortions are registered in The Register of Pregnancy Termination (a separate 
registry), which was established in 2006. Induced abortions are legal during the first 12 
gestational weeks in Norway. From the 13th gestational week, a medical committee has to 
decide whether an abortion could be performed or not, upon application from the pregnant 
woman. In the MBRN database, only the late-induced abortions are included, usually based 
on ultrasound-detected foetal defects, and spontaneous abortions are only occasionally 
registered, depending on the duration of the pregnancy.
Gestational age is based on the date of the last menstruation, and since 1999, also on 
ultrasonographic estimations of gestation. Vital status of the newborn is registered as 
stillborn, alive at birth, death during the perinatal period (the first seven days of life), or 
death during the first three years of life. Immediate post-natal status is also given using 
Apgar score at one and five minutes, which has been registered since 1977. Delivery is 
notified as spontaneous or induced, and the use of caesarean section is listed, usually with 
additional information stating whether this operation was done electively or as emergency 
surgery. 
Statistics Norway (SSB) 
SSB compiles individual-level information on all citizens in Norway. The institution was 
originally established as the Central Bureau of Statistics in 1876. For the present thesis, vital 
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status and educational status was provided by SSB. Educational status was used as a proxy 
variable of socioeconomic status in the analyses, given as education level at the time of 
inclusion. Educational level was categorised according to the total duration of education as 
ORZ\HDUVPHGLXP–\HDUVKLJK\HDUVRUXQNQRZQ
The Cause of Death Registry 
Underlying cause of death is registered, according to the International Classification of 
Diseases (ICD), since all deaths are reported by doctors who are required to complete a 
death certificate. The Section for Health Statistics at Statistics Norway is the Data Processor 
for the Cause of Death Registry, while the Norwegian Institute of Public Health is the Data 
Controller. Updated information about the date of death is provided to the CRN once a 
month, and cause(s) of death are provided once a year. 
The Norwegian Population Register  
The control population for paper I and II was provided by the Norwegian Population 
Register. The register keeps demographic information on all citizens of Norway, including
date of birth, date of death or emigration, and other personal information like marital status, 
children’s date of birth etc. For this project, permission was granted by the Norwegian 
Population Register to draw cancer-free controls. The MBRN has access to the database of 
the Population Register, and established the control population. The data controller for the 
Norwegian Population Register is the Norwegian Tax Administration.
Approvals  
With permission from the National Data Inspectorate, the Regional Committee for Medical 
Research Ethics, and the registries/data controllers, data from the Cancer Registry were 
merged with data from the other data providers described above. No identifying information 
was provided to the researchers.
Data linkage and file construction 
For all papers, all malignant neoplasms according to the ICD-7 (140–207) were included, 
except basal cell carcinomas. In the case of multiple cancers in one person, only the first 
registered invasive malignancy was used in the analyses. Other eligibility criteria 
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compressed a histological confirmation and diagnosis prior to emigration or death, thus 
excluding cases diagnosed by autopsy. All cancer types combined were analysed, followed 
by separate analyses of the most frequent cancer types for the age group included. The most 
frequent cancer types were testicular, cervical, ovarian, breast, and thyroid cancer, 
malignant melanoma, brain tumours, Hodgkin’s and non-Hodgkin lymphoma, and 
leukaemia. Expressions like pregnancy and pregnancy outcomes are used similarly for both 
genders in papers I and II. In the following, each paper will be described regarding materials
and methods, for further details see each of the papers. An overview is listed in Table 3 at 
the end of this chapter.
Paper I: Pregnancy after adolescent and adult cancer: a population-based 
matched cohort study 
Data from the CRN and the MBRN were merged, according to Figure 3, giving a total of 
27,556 cancer survivors. To obtain the complete reproductive history for each person, we 
restricted our study to cancer patients who were 16 years or younger in 1967, when the 
MBRN was established. 
 
Figure 3 
Flowchart displaying the register linkage and study populations for paper I and II. 
*The MBRN constructed the control population file after permission from the National Population 
Register.  
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The main outcome was fertility after cancer, measured as the first post-cancer pregnancy. 
All registered pregnancies, regardless of duration and outcome, but with the date of last 
menstruation subsequent to the date of diagnosis, was included. An assigned “date of 
diagnosis” was defined for the controls, using the date of diagnosis for the matched 
survivor. For simplicity, the expression “post-cancer pregnancy” was used both for male 
and female cancer survivors and controls. We included only stage I patients with cervical 
and ovarian cancer (except for germ cell ovarian cancer), because the treatment of stage II–
IV patients usually results in infertility. Borderline ovarian tumours were excluded. Sub-
analyses of ovarian cancer were stratified according to epithelial stage I and germ cell or 
sex-cord tumours, because of prognostic and therapeutic differences. 
Because cancer treatment information at an individual level is scarce in the CRN, we made 
an overview of general Norwegian treatment guidelines throughout the study period for the 
cancer types of interest. Stratification of the different treatment-related periods and 
interpretations were based on this table (see Table 1 in Paper I).160
Paper II: Birth outcomes among offspring of adult cancer survivors: a population-
based study 
From the cohort of cancer survivors from paper I, all female and male survivors with at least 
one singleton pregnancy registered after cancer in the period 1967 to 2006 were selected 
(n=5,085). For the controls, the matching was broken and only those with at least one 
pregnancy registered in the study period, were used (n = 146,728, see Figure 3 for more 
detail). 
The main dependent parameters were pregnancy outcomes after cancer, which were 
analysed in two different parity subgroups for each gender. Nulliparous (first pregnancy 
ever after cancer) and primiparous (one pregnancy before and one after cancer) survivors 
were analysed. For comparison, we used all controls with at least one and two pregnancies,
respectively.  
The main pregnancy outcomes analysed were perinatal death, low birth weight (LBW, 
<2500g), preterm and very preterm birth (born <37 and <32 gestational weeks, 
respectively), low Apgar score161 at five minutes (below 7), and congenital anomalies 
42
according to EUROCAT.162 We also evaluated mean birth weight, the use of IVF/ICSI, the 
occurrence of pre-eclampsia, and delivery by caesarean section. 
Pregnancies shorter than 22 weeks of gestation, or with infants less than 500 g, were defined 
as spontaneous abortions (in accordance to WHO) and excluded. Consequently, perinatal 
death was defined as stillbirths with a gestational age of 22 weeks or more and weighing 
more than 500 g, death during delivery, or death during the first seven days of life. For 
analyses of preterm birth, misclassifications of gestational age were removed on the basis of 
current birth weight-by-gestational age standards, excluding z-scores larger than 4.163
Congenital anomalies defined by EUROCAT excludes singular minor anomalies, those 
anomalies which are not truly congenital in origin (e.g. associated with immaturity at birth), 
and conditions poorly specified or often detected at a later stage of the infant’s life.
Examples of minor anomalies which are excluded, if they are isolated, are syndactyly, short 
fingers, haemangioma, pigmented nevus, torticollis, epicanthic folds, hiatus hernia, 
Meckel’s diverticulum, and accessory or absent rib162. Congenital hip dislocations were also 
excluded from our analyses, as they might be detected at a later stage than the hospital 
examination.
Paper III: Cause-specific survival for women diagnosed with cancer during 
pregnancy or lactation: A registry-based cohort study 
Merging of registry data was performed according to Figure 4. Pregnant at diagnosis was 
defined as being diagnosed with cancer within the same month as their last menstruation 
until the date of delivery. Lactation period was defined as from the date of delivery to six 
months postpartum. If they experienced perinatal loss, the lactation period was defined as 
until two months postpartum. The women were not necessary lactating, but we wanted to 
focus on the post-natal period and the associated hormonal and breast tissue changes. 
Females with subsequent pregnancies were defined as those having a pregnancy with last 
menstruation dated after the date of diagnosis. The comparison groups for analyses were 
females diagnosed with cancer, but without pregnancies associated with cancer diagnosis or 
after cancer, for simplicity, these were called non-pregnant. We analysed all sites combined 
and the most frequent cancer types for this age group. 
43
The main outcome was cause-specific survival, defined as death by the same cancer type as 
that initially diagnosed, and with a date of diagnosis before the date of death. 
Figure 4 
Flowchart displaying registry linkage and study population for paper III.  
 
Covariates 
Calendar year 
We have studied a time period of almost 40 years, from 1967. During this period, several 
new cancer treatments have changed the prognosis dramatically, for instance the 
introduction of cisplatin. For pregnant women, the follow-up has changed as well during
this period, most essentially with ultrasound examinations, but also with welfare 
improvements like longer periods of maternity leave. For paper I, diagnostic periods were 
established according to the treatment changes for the period 1967-2004, listed in Table 1 in 
the paper. For paper II, birth periods were used, instead of diagnostic periods, from 1967-
1975, and further in 5-year intervals. For the third paper, the following diagnostic periods 
were used: 1967-1984, 1985-1994, and 1995-2002, based on timing of the main therapeutic 
changes during the period. 
Age 
Age at diagnosis might influence the prognosis for certain cancer types. Furthermore,
maternal age is linked to risk patterns for several pregnancy complications and birth 
outcomes. For paper I, the survivors and controls were age-matched on the time of the 
Study population I 
41,464 non-pregnant women 
516 pregnant women 
531 lactating women 

Study population II 
40,200 non-pregnant women 
2,311 women with 
subsequent pregnancies 
MBRN 
 
Reproductive history for 
the period 1967 and 2004 
CRN 
42,511  
women diagnosed with 
cancer at 16-49 years, 
between 1967 and 2002 
44
survivor’s diagnosis, so there was no need to adjust for age in the model. In paper II, the 
matching was broken, and we adjusted for maternal age (age at birth) in 5-year intervals 
(16-20, 20-24, 25-29, 30-34, and 35-45 years). In paper III, we used age at diagnosis, 
grouped into 5-year intervals, except for the first age group, 16-24.
Extent of the disease 
In all papers, we adjusted for the extent of disease in terms of localised, regional, distant and 
unknown. Exceptions from this categorisation are cervical and breast cancer, brain tumours, 
and haematological malignancies, as previously described.
Parity 
We adjusted for parity in paper I, categorised as childless, one child, and two or more
children at the time of cancer diagnosis. In paper II, we stratified on parity by analysing 
nulliparous and primiparous individuals separately. For the cancer survivors, nulliparous 
meant the first pregnancy after cancer, and primiparous was used to mean having one 
pregnancy before cancer, and at least one after, where the second was focused on. The 
expressions nulli- and primiparous are used for both gender. The risks for stillbirth, LBW 
and preterm birth are higher for the first pregnancy than the second, and the risk pattern is 
not a linear function for, say the first three pregnancies.56
Educational level 
We used adjustments for educational level as a proxy for socioeconomic status. In papers I
and II, we adjusted for educational level at the time of diagnosis for the survivors and at 
inclusion for the comparison cohort. Categorisation based on the number of years of 
education gave four levels: low (1-9 years, elementary and secondary school), medium (10-
12 years, high school), high (13 years or more, college and/or university), or unknown. The 
proportion of unknown was 3% for survivors and 8% for controls in paper I, and 17% for 
survivors and 35% for controls in paper II. Educational level is not properly registered for 
immigrants, and is also underreported for the earliest birth cohorts.
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Statistical analyses 
For all papers, standard descriptive methods were applied, using SPSS, with median and 
range or mean and standard deviation for continuous data and counts and proportions for 
categorical data. All tests were two-sided and p-values <0.05 were considered statistically 
significant, except for paper III, where p-values <0.01 were chosen. Hazard rates (HRs) or 
odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated for both crude 
and adjusted analyses. 
Fertility after cancer (paper I) 
We used the Cox model or proportional hazards regression to compute post-cancer 
pregnancy rates for cancer survivors compared with those of the controls. The model was 
developed by D.R. Cox in 1972, and assumes that the ratio of the hazards comparing 
different exposure groups remains constant over time. The proportional hazards assumptions 
were checked by visual inspection of log–log plots. We performed separate analyses for 
each gender, for all cancer types seen together, and for selected diagnoses. We stratified by 
matched sets, consisting of a survivor and his/her five corresponding controls. The 
observation time was defined as the interval from the actual or the assigned date of 
diagnosis to the date of the first birth after cancer. Censoring was made for death, 
emigration, or when the person reached the age of 46, or December 31, 2006, whichever 
occurred first. 
Cumulative hazards distributions display how the hazards vary if an event varies with time. 
Since the prognosis is quite poor for several of the cancer types included, death as a 
competing event to initiating a pregnancy after cancer was thus incorporated into the 
analysis, and was depicted as cumulative incidence. The competing risk approach is used as 
a supplement to the proportional hazards model, which involves treating the competing 
events by censoring.  
Birth outcomes (paper II) 
Descriptive analyses with Chi-square and multiple logistic regression models were used to 
compare birth outcomes for survivors and controls. Multiple logistic regressions predict the 
probability of an event, and take into account several explanatory factors (confounders). The 
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estimate is given as an odds ratio. The model compares the odds of, for example, LBW for 
the offspring of cancer survivors (the exposed ones) to the odds of LBW for the offspring of 
the controls (not exposed). Further, we used a univariate ANOVA model to assess mean 
birth weight, both crude and adjusted for maternal age. The same model was repeated to 
assess mean birth weight in a cohort excluding malignant melanoma patients, as previously 
described, to simulate the selection used in the hospital-based study by Magelssen et al.2
Cause-specific survival (paper III) 
Using the Cox model, two different subsets were analysed with cause-specific survival as 
the outcome. The first subset explored survival if the cancer was diagnosed during 
pregnancy or lactation, and the second investigated survival in cancer survivors with at least 
one subsequent pregnancy. We used analyses of Schoenfeld residuals in order to test the 
proportional hazard assumption. Multivariable analyses were conducted to assess potential 
confounding by the covariates listed above. 
For the second analysis, we introduced a time-dependent variable. All survivors started out 
as non-pregnant (reference group), and the women who had any pregnancy starting after the 
date of diagnosis were moved into the post-cancer pregnancy group at the date of delivery. 
The women who finally constituted the post-cancer pregnancy group contributed time at 
risk in the reference group until the date of the first delivery after cancer, from which date 
the follow-up started. 
With death as the outcome event in both analyses, end of follow-up was defined as reaching 
age 60, emigration, or 31 December, 2004, which led to censoring. Trends in proportional 
changes per year of incidence of cancer diagnosed during pregnancy or lactation were tested 
by a log-linear model with calendar year as a continuous variable. 
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Table 3 
 Overview over the three papers included in the thesis, regarding material and methods. 
Papers 
included
Paper I – fertility after 
cancer
Paper II – birth 
outcomes
Paper III – cause-specific 
survival
Title Pregnancy after adolescent 
and adult cancer: a 
population-based matched 
cohort study
Birth outcomes among 
offspring of adult cancer 
survivors: A population-
based study
Cause-specific survival for 
women diagnosed with 
cancer during pregnancy or 
lactation: a registry-based 
cohort study
Main 
purpose
Compare incidence of 
pregnancies after cancer 
with the number of 
pregnancies in a cancer-
free, age-matched controls 
group, analysed separately 
for females and males
Compare birth outcomes 
among the offspring of the 
cancer cohort and the 
cancer-free cohort.
Analysed separately for 
females and males and by 
parity 
i)  in nulliparous 
ii)  in primiparous 
Compare survival in
i) females with cancer during 
pregnancy or lactation
with  non-pregnant females 
with cancer 
ii) females with subsequent 
pregnancies with females 
without pregnancies after 
cancer
Study 
design 
Population-based historical 
cohort
Population-based historical 
cohort
Population-based historical 
cohort of female cancer 
patients
Study 
population; 
definition
Survivors: Females and 
males, diagnosed in the 
period 1967-2004 at age 16-
45 years
Controls: Five per survivor, 
matched on age and gender. 
The controls were given an 
assigned date of diagnosis
Survivors: Females and 
males, diagnosed 1967-2004 
at age 16-45 years and with 
a subsequent pregnancy 
(1967-2006)
Controls: All from paper I 
with at least one pregnancy 
in the period 1967-2006
Females diagnosed with 
cancer in the period 1967-
2002, at age 16-49 years old.
Follow-up
periods
Cancer: 1967-2004
Pregnancies: 1967-2006
Cancer 1967-2004
Pregnancy outcome: 1967-
2006
Cancer: 1967-2002
Death/pregnancies: 1967-
2004
Observation 
period; 
definition
From the actual or assigned 
date of diagnosis to the date 
of the first birth after 
cancer, death, emigration, 
age of 46, or December 31, 
2006, whichever occurred 
first
Not relevant From the date of diagnosis 
until date of death, 
emigration, age of 60, or until 
December 31, 2004, 
whichever occurred first
Statistical 
approach
Cox model, competing risk 
(cumulative incidence)
Logistic regression Regular Cox model and time-
dependent Cox model
Adjustments -Diagnostic periods: 
according to treatment 
periods (Table 1, paper I)
-Pre-diagnostic parity: 0, 1,
2+
-Extent of disease*: 
Localised, regional, distant, 
and unknown. 
-Educational leYHO/RZ
yrs), medium (10-14 yrs), 
KLJK\UVXQNQRZQ
-Birth periods: 1967-1975, 
further in 5-year intervals
-Maternal age: <20 years, 
20-24, 25-29, 30-34, 35+
-(GXFDWLRQDOOHYHO/RZ
yrs), medium (10-14 yrs), 
KLJK  \UV DQG
unknown
-Diagnostic periods: 1967-
1984, 1985-1994, 1995-2002
-$JH DW GLDJQRVLV  -
29, 30-34, 35-39, 40-44, 45-
49
-Extent of disease: Localized, 
regional, distant, and 
unknown. 
*For gynaecological cancer, FIGO stage I-IV, breast cancer stage I-IV (localised, regional lymph node 
metastases, direct tumour extension to the chest wall or skin, or distant metastases). Brain tumours 
and non-solid tumours are not classified by stage or extent. See table 1 in paper I for the selected 
stages included in the analyses. 
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SUMMARY OF RESULTS 
Fertility after cancer (Paper I) 
Cancer survivors had, in general, lower pregnancy rates than controls, but the rate was 
higher in males than in females (HR = 0.74 [95% CI 0.71–0.78] and HR = 0.61 [95% CI 
0.58–0.64], respectively). However, both male and female survivors of malignant melanoma 
and thyroid cancer did not differ from their controls. The other malignancies with high 
pregnancy rates after cancer were testicular cancer, Hodgkin lymphoma among males, and 
non-Hodgkin lymphoma among females. In contrast, the lowest hazard rates for pregnancy 
occurred in female survivors of leukaemia, breast, or cervical cancer stage I (Figure 5). 
Figure 5 
Pregnancy rates after cancer for both female and male cancer survivors. The columns represent HR, 
and the error bars 95% CI. 
The pregnancy rates increased during the study period for all ovarian cancer types of stage I 
(HR = 0.19 [95% CI 0.11–0.32] to HR = 0.67 [95% CI 0.49–0.90]), testicular cancer (HR = 
0.61 [95% CI 0.43–0.86] to HR = 0.76 [95% CI 0.70–0.83]), and for men diagnosed with 
HL (HR = 0.68 [95% CI 0.53–0.87] to HR = 0.87 [95% CI 0.73–1.04]). When taking parity 
into account, female survivors had lower pregnancy rates if they had at least one child at 
diagnosis compared to those childless at diagnosis (HR = 0.52 [95% CI 0.48–0.56]  versus
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HR = 0.73 [95% CI 0.67–0.78]), while for male survivors, parity did not have any 
difference in the rate of initiating a pregnancy after cancer. Successful assisted reproductive 
technologies (ART) were used by 6% of male cancer survivors to initiate a pregnancy after 
cancer, while only 2% among the controls became pregnant by ART (p<0.001). For 
females, the use of ART was similar for survivors and controls (2% for both groups). 
Competing-risk plots were made to determine whether there was a catch-up effect during 
the 15 years of observation after diagnosis, but no real catch-up effect was observed for the 
cancer survivors compared to the controls for any of the malignancies analysed.
Birth outcomes (Paper II) 
The infants born to nulliparous female survivors (having their first pregnancy after cancer) 
had an increased risk of preterm delivery (HR = 1.30 [95% CI 1.05–1.61]) and LBW (HR = 
1.26 [95% CI 0.99–1.60]). Nevertheless, when restricting the analyses of LBW to term 
infants, the increased risk of cancer survivors’ offspring disappeared. In comparison, for 
primiparous female survivors, the outcome of the second pregnancy differed from the 
controls, with a higher risk of LBW and preterm birth. Even when restricted to infants born 
at term, the risk of LBW was still doubled. A borderline significant increase of perinatal 
death was seen for primiparous female survivors, with OR=1.92 (95% CI 0.98–3.76, Figure 
6). 
There was no increased risk of congenital anomalies for the offspring when analysing all 
cancer types combined for each gender and parity group separately, not even when 
restricted to analyses of females giving birth within two years. When analysing the most 
frequent cancer types separately, the only increased risks of malformations were found in 
offspring of primiparous breast cancer survivors (OR=3.49 [95% CI 1.24–9.82]), and in 
offspring of nulliparous ovarian cancer survivors (OR=3.23 [95% CI 1.54–7.23]). The 
different anomalies are displayed in Table 5. In breast cancer survivors who were only 
initially treated by surgery, the risk estimate was still elevated, but not significantly 
(OR=1.65 [95% CI 0.22–12.30], not tabulated). 
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Figure 6 
Effects on birth outcomes to primiparous female cancer survivors compared to their controls with 
similar parity. HRs with 95% CIs for the outcomes of the first birth, the one before cancer diagnosis, 
is depicted for comparison.  
ART was used more frequently among male survivors than controls to achieve a pregnancy 
after cancer, both among nulliparous (HR = 1.83 [1.35–2.49]) and primiparous (HR = 4.01 
[95% CI 2.53–6.35]) survivors. Surprisingly, ART was also frequently used among 
primiparous females to initiate the pregnancy before cancer (HR = 2.85 [95% CI 1.46–
5.56]), but they did not differ from their controls regarding the use of ART for the 
pregnancies after cancer. 
Primiparous female survivors had doubled the risk of giving birth by caesarean section 
(HR = 1.75 [95% CI 1.43–2.15]), and pre-eclampsia also occurred more frequently among 
primiparous female survivors compared to their controls, (HR = 1.58 [95% CI 1.04–2.39]). 
For a subgroup of primiparous females where the malignant melanoma survivors were 
excluded (to compare with the cohort and results in the study by Magelssen et al.2), a 
significant difference in mean birth weight was demonstrated for the second sibling, with 
lower birth weight for the survivors’ than controls’ offspring (depicted in figure 2 in paper 
II). Otherwise, mean birth weight was similar for offspring of survivors and controls.
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Figure 7 
Effects on birth outcomes to primiparous male cancer survivors compared to their controls with 
similar parity, depicted as HRs with 95% CIs for the first and second birth. 
Cause-specific survival (Paper III) 
Our results revealed that, in Norway, about 1 in 2000 pregnancies is associated with cancer, 
diagnosed during pregnancy or the lactation period (first six months post-partum). The 
incidence of cancer associated with pregnancy increased during the study period (Figure 8).
Figure 8 
Annual incidence of cancer diagnosed during pregnancy or lactation, using 3-year moving averages, 
shown as proportions per year per 100,000 pregnancies. Annual incidence of cancer diagnosed 
during pregnancy or lactation, using 3-year moving averages, shown as proportions per year per 
100,000 pregnancies. Reprinted with permission. ©2009 American Society of Clinical Oncology. All 
rights reserved. Stensheim et al. JCO 2009;27:45-51.164 
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The mean annual incidence of cancer during pregnancy in the period was 24.5 per 100,000 
pregnancies and for cancer during the lactation period 27.7 per 100,000 pregnancies. The 
annual increase during the period was 2.5% (95% CI 1.7–3.3) and 1.6% (95% CI 1.0–2.4), 
respectively, for cancer diagnosed during pregnancy and lactation. 
The most frequent cancer types during pregnancy or lactation were found to be malignant 
melanoma, cervical cancer, and breast cancer, in that order (Figure 9). The survivors of 
malignant melanoma, thyroid cancer, and lymphoma and leukaemia most frequently 
become pregnant after cancer (Figure 10).
Figure 9 
The order of the cancer types on the x-axis is reflecting the frequency of the different cancer types 
for all females who were diagnosed in the age group 16-49 years. The columns depict the numbers 
diagnosed with the different cancer types during pregnancy or lactation. 
 
Figure 10 
The most frequent cancer types diagnosed in females with subsequent pregnancies, n = 2,311. 
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For all sites combined, no differences in cause-specific death were seen for the pregnant and 
lactating groups compared to their controls. Patients with breast (HR, 1.95 [95% CI 1.36-
2.78]) and ovarian cancer (HR, 2.23 [95% CI 1.05-4.73]) diagnosed during lactation had an 
increased risk of cause-specific death. 
Figure 11 
Hazard rates for survival of women diagnosed with cancer during pregnancy or during the lactation 
period. The upper CI limit for thyroid cancer diagnosed during pregnancy was 35.9. No one 
diagnosed with thyroid cancer died in the lactation period group. 
Diagnosis of malignant melanoma during pregnancy also increased the cause-specific risk 
of death (HR=1.52 [95% CI 1.01-1.22]), but if localisation of the melanoma was adjusted 
for, the HRs were reduced to 1.45 (95% CI 0.96-2.21). We found a difference in the site 
distribution of melanomas between those diagnosed during pregnancy and those who were 
not pregnant, with a higher frequency of head, neck, and trunk melanomas among the 
pregnant group, while the non-pregnant individuals had a higher frequency of leg 
melanomas. In an additional analysis, we adjusted for tumour depth according to Breslow,
when available (55% of the patients), but did not find any difference in survival compared 
to the controls. Finally, we combined the groups diagnosed with malignant melanoma 
during pregnancy and during lactation, and did not find a worse survival in comparison with 
the non-pregnant population: HR=1.33 (95% CI 0.95-1.86). 
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For all sites combined, the risk of cause-specific death was significantly decreased for 
women who had subsequent pregnancies (HR=0.49; 95% CI 0.41-0.59), and similar 
findings were seen for cervical cancer and leukaemia and lymphoma with subsequent 
pregnancies, while the other cancer types analysed separately did not differ from the cancer 
survivors, with no post-cancer pregnancies (see Figure 12).
Figure 12 
HR with 95% CI for women pregnant after cancer, compared with women with no pregnancies after 
cancer. The upper CI limits for thyroid and ovarian cancer were 8.8 and 3.0, respectively. 
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DISCUSSION 
Methodological considerations 
Design 
This thesis includes three observational cohort studies. A cohort is a defined group of 
individuals who are followed from a given time point or inclusion event, over a period of 
time, in order to explore whether there are causal relationships between the occurrence of a 
disease (or another event) and future outcome. It is the archetype for all epidemiologic 
studies, in contrast to case-controls studies, which are classified as the second most 
convenient design for epidemiologic studies. A case-control study is based on a sample 
from a source population. Incidence rates or risks can be calculated from a cohort design, 
which is well-fitted to study many types of outcomes.165;166
Observational studies can be retrospective in the sense that data have already been collected, 
but prospective in the meaning of following individuals from, in our case, cancer diagnosis 
until a future event takes place. Both cohort and case-control designs offer high precision. 
The accuracy of observational epidemiologic studies might be influenced by two types of 
errors, systematic and random errors. Systematic errors result from selection bias, 
information bias, and confounding, whereas random errors are related to statistical 
precision. This will be further discussed in the following sections. 
For paper I, all cases with cancer diagnosed in the age group 16-45 years were followed 
from a cohort of the entire Norwegian population of all males and females born in 1951 or 
later. For every male and female with cancer, five age- and gender-matched controls were 
randomly selected from the Norwegian Population Register to assess the pregnancy rates 
after cancer, and for the controls after the assigned date of diagnosis. It can be thought of as 
a cohort study, with a survivor cohort (exposed to cancer) compared to a sample of the 
entire cancer-free cohort. Another useful design would have been a typical cohort design, 
where the comparison group was made up of the whole cancer-free population in Norway
for the chosen age group and period. Further, we could have started follow-up at the time of 
birth, and not from the time of cancer diagnosis, in order to determine to what degree cancer 
survivors had a first birth compared to the general population, as done by Syse et al.24
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Collecting a random sample from the cohort of cancer-free persons offers less statistical 
precision than using the full cohort, but similar estimates are expected to be achieved by 
using five or more controls per case, compared to using the whole population as controls.166
In these preparations, we also used a model where matching was ignored and age was 
adjusted for as a covariate. This gave similar results to the matched model. 
In paper II, a cohort of all males and females diagnosed with cancer and with registered 
pregnancies after cancer was selected from the material in paper I. They were followed to 
assess whether the offspring had adverse birth outcomes or not, compared to a sample from 
the general population. The matching from the original material (see paper I) was dissolved 
to make estimation of birth outcome possible with adjustment for maternal age. The initial 
file was matched on the day of birth. This design can also be looked upon as a case-control 
study nested within a cohort (of all Norwegians with at least one pregnancy). The mean age 
differed slightly among the survivor and control groups, and the number of patients for each 
birth period differed as the control cohort was larger for the first period. To take care of this 
imbalance, we used multivariable statistical analyses with adjustments for age and birth 
calendar period. To avoid this step of breaking the originally matched design and the 
possible insecurity introduced, a preferable design would have been to use all cancer-free 
individuals registered in the MBRN in the chosen period as controls (as done by Magelssen 
et al.2). 
Since Magelssen et al.2 had published a mono-institutional study about birth outcome after 
cancer based on material from the Norwegian Radium Hospital (NRH) in 2007, we wanted 
to make close comparisons. Therefore, we excluded malignant melanoma survivors from 
sub-analyses on birth weight and the main pregnancy outcomes for the offspring to compare 
estimates. More than 30% of the females and about 20% of the males in our material were 
diagnosed with malignant melanoma, while the corresponding figures in Magelssen’s 
material based on patients at the NRH were quite small: 5% and 1%, respectively.2 The 
majority of those reported to the CRN with malignant melanoma for this age group likely 
had stage I disease, with no need for systemic treatment.
In paper III, a historical cohort design was applied, using all females with a cancer 
diagnosis in the age group 16-49 years. They were followed to assess survival, comparing 
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groups related to the time of pregnancy (pregnant at diagnosis, lactation period when 
diagnosed, or with a subsequent pregnancy, compared to those who were nulliparous or 
experienced all their pregnancies before the time of cancer diagnosis). 
Survival analyses 
We have performed survival analyses in two papers. It can also be applied to non-fatal risks 
as future events following an exposure, like getting pregnant or not, after a diagnosis of 
cancer. 
Survival might be defined as observed or relative. Observed or overall survival is a measure 
of the proportion of individuals who survived for a specified time period without addressing 
the cause of death, often starting at the time of cancer diagnosis. For example, we often give 
prognostic information about cancer in five-year survival, which is based on the proportion 
being alive five years after diagnosis. Relative survival relates observed survival to that
expected in a group from the general population with similar age and gender, which is 
known as net survival. In paper I, we used the Cox model to investigate pregnancy-rates 
after cancer. We analysed cause-specific survival in paper III, which is sometimes called 
corrected survival. Cause-specific survival is a net survival measure representing cancer 
survival in the absence of other causes of death. Cause-specific survival is corrected by 
censoring those who died of causes other than cancer. We have used the expression cause-
specific survival. Since the risk estimates are representing a risk of death, we could instead 
have called it cause-specific mortality. 
As cause of death, we have used the underlying cause of death. Since the correct diagnosis 
might be difficult to determine sometimes, especially in elderly people, we restricted the 
follow-up time to age 60. Autopsies are seldom performed in Norway nowadays (less than 
10% of all deaths), but more often in younger persons. The cancer diagnosis is usually the 
underlying cause of death if a person still had symptoms of his or her malignancy. A recent 
paper revealed that cancer as the underlying cause of death had the highest accuracy 
compared with other diagnoses, when undertaking autopsy findings in addition to death 
certificate information. They also found a small underestimation of cancer as the cause of 
death.167 It is a known limitation with cause-specific survival analyses that for some 
survivors, the malignancy might have contributed to the cause of death, but they are still 
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given a non-malignant diagnosis. There are also other reasons for the cause of death 
information being unreliable or unknown. For example, if a cancer has metastasised to 
another site, the death certificate may list cancer of the metastasised site as the cause of 
death. One possible way to address this problem is to only include individuals with one 
primary cancer and define the cause of death as all cancers. However, we listed only nearby 
sites as a real cause-specific death, and censored those who had a totally different cancer 
diagnosis as cause of death than the initial diagnosis listed in the CRN. We also assessed 
overall survival at age 60, which, in numbers, differed by 1-3% from the number classified 
with a cause-specific death.164
In paper I, we performed competing-risk-analyses in addition to Cox regression, since the 
risk of death for some cancer types and stages are competing with the probability of 
achieving a pregnancy after cancer, at least for women. Therefore, we performed competing 
risk plots to estimate the cumulative incidence of pregnancies after cancer, in comparison 
with controls. Estimates were also computed, and in comparison to the hazard rates obtained 
from Cox regression, we found very similar estimates. Death is treated as censoring in the 
Cox regression. At least for certain cancer types and periods, the risk of death was higher 
than the probability of having a pregnancy after cancer, for example for breast cancer, while 
malignant melanoma and thyroid cancer survivors showed equal probabilities to conceive 
after cancer as their controls, even if the risk of death was higher for the cancer survivors 
than for controls (Figure 13). We expected a small catch-up effect for some of the cancer 
types with early recurrence, but no such convincing effect was seen by inspecting the plot. 
Probably, there might be a minimal such effect seen for Hodgkin lymphoma among females 
in the period 1967-1987 (figure 2, paper I). This might reflect the competing risk and 
decreased fertility for the first years after cancer, as well as the general advice given to 
cancer patients, to delay pregnancy for at least two years after diagnosis.
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Figure 13  
Competing risk plots. The x-axis shows time since cancer diagnosis and the y-axis measures 
cumulative risk of death versus probability of having a pregnancy after cancer. 
The time-dependent Cox regression used in paper III is chosen to take care of two events, 
diagnosis of cancer, and the following event, a subsequent pregnancy. Kaplan-Meier or 
regular Cox model analyses are not suitable for such situations, since all females in the 
group who had a subsequent pregnancy stayed alive at least until the first birth. In contrast, 
females in the comparison group, they who did not have pregnancies after cancer, were at 
risk of dying from day one in the follow-up period. Studies have been performed without 
taking this into account.168
Validity 
Validity is divided into two components. Internal validity reflects whether the observed 
findings are representative for the entire groups studied. Internal validity is influenced by 
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selection bias, information bias, and statistic validity, which are explained below. The 
observations in this thesis are looked upon as valid and representative for the Norwegian 
population (internal validity). External validity reflects to what extent the findings could be 
applied to another population than the group studied, representativeness. External validity is 
influenced by study design which is influenced by random or systematic errors. 
The comparison groups used in paper I and II might be theoretically healthier than the 
general population they are sampled from and meant to represent, as they are cancer-free at 
least until the time of diagnosis for the index case. Practically, this is negligible, also since 
the age group studied is younger than 46 years. 
Our findings might be valid for other populations similar with ours, at least the 
Scandinavian populations, but cancer incidence patterns and treatment guideline factors 
linked to society, economy, educational level, and social welfare system will influence to
what degree the external validity can be accounted for in all populations (external validity). 
One might argue that parts of the cancer cohort studied represent outdated treatment. This 
might reduce the generalisability of our results to current cancer patients, both in our 
population and worldwide. Treatment and diagnostic procedures, age at first birth, and the 
mean number of children have changed during the study period. Still, the understanding of 
biological effects of previous cancer treatment might be of interest, like the finding of 
increased numbers of pregnancies registered among survivors of ovarian or testicular 
cancer, and among males diagnosed with HL.160 The understanding of the diagnostics and 
treatment for the more historical proportion of the cohort is still of relevance, in the 
perspective of cancer survivorship research. 
Selection bias  
Such bias results from the selection of participants for a study, where the relation of the 
exposure and the disease or event studied, is differently dispersed among those included and 
those not. For registry-based studies like ours, the observations are most likely prevented 
from selection bias. Mandatory registration of cancer and births prevent selection bias. The 
control population for study I could possibly have been influenced by selection bias if the 
individuals chosen were matched on more than age and gender, and for study II the controls 
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have a little different age distribution, the control of which is attempted through adjustments 
for maternal age and calendar period. 
For simplicity, we excluded survivors of cervical and ovarian cancer stage II-IV in paper I, 
since the treatment usually requires hysterectomy and thereby makes future pregnancies 
impossible. One might argue that treatments for other cancer types also imply a high risk of 
infertility. Since no detailed treatment information was available, however, we chose to 
adjust for stages of other cancer types, which did not necessarily impose infertility. If not 
fully adjusted, this selection of eligible individuals might give an estimate reflecting a 
heterogeneous group, for example for breast cancer survivors, since some of them might be 
infertile after treatment.
Another type of selection bias, which is present in paper III, is self-selection when it comes 
to having a child after cancer. This is called the “healthy mother effect” and influences all 
analyses comparing survival among cancer survivors with and without subsequent 
pregnancies.99 The explanatory factors for the healthy mother effect are most likely better 
prognosis (low grade tumour) and less cancer treatment, eventually lower age at diagnosis 
than those not getting pregnant afterwards, and being in good health after cancer. 
Information bias 
If there are errors in the measurements of variables regarding exposure and outcome, 
information bias is present, which can lead to false conclusions. In registry-based studies,
the risk of information bias is substantially reduced, as recall bias is not a problem. Still, 
there might be information bias introduced by misclassifications and random errors, 
including typing errors and data processing errors. Being misclassified describes the 
situation where individuals are placed in the wrong category, for example if those with 
cancer in situ are categorised as having invasive cancer. Misclassifications could be of two 
types: differential misclassifications and non-differential. About 0.5-1% of typing errors 
must be accounted for in registry-based materials, but such errors are likely to be similarly
spread among cases and controls, and are usually disregarded.
A differential misclassification occurs when the classification of outcome is dependent upon 
the status of the exposure, or vice versa. This is the situation when misclassification may 
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vary between groups (e.g. is differently dispersed among survivors and controls). For 
example, one might think that the detection and registration of congenital anomalies among 
offspring of cancer survivors could be made earlier than for the cancer-free population, 
since there is a reason for higher awareness in the first group. Since the registrations are 
made upon examinations in hospital during the first three to four days of life, this type of 
error should be minimised.
A non-differential misclassification occurs when the probability of misclassification is the 
same, regardless of the study group, for instance survivors and controls. Non-differential 
misclassification will introduce bias towards the null, leading to an underestimation of the 
associations. The registration of fathers in the MBRN is based on information from the 
mother. This might lead to a number of fathers that only are social, not biological fathers. It 
is likely that there are no differences among cancer survivors and the cancer-free population 
in this regard. There is also a general underestimation of the number of fathers, up to 2%,
since not all fathers are reported to the MBRN.27
Potential misclassification of exposure variables 
Less than 3% of the cancer cohort used in this material is registered with more than one 
malignant diagnosis. The information about the second and eventual subsequent cancers is 
not used, and since recurrences are not registered, we have only focused on the first invasive 
diagnosis for all three studies. 
Regarding the extent of disease or stage, registration has varied through the period studied. 
In cases lacking information, the code “unknown” should be used, but this parameter seems 
to have been used more frequently for some malignancies than others during several 
periods. Unfortunately, this results in more than 30% of cases having unknown extent 
during several calendar year periods, illustrated by breast cancer in paper I, for instance. 
The registrations of miscarriage tend to be underreported for the beginning of the second 
trimester. Even if the reporting is mandatory from gestational week 12 (16 before 1999), 
late miscarriages (gestational week 12-21) usually lead to hospitalisation, but in the 
Gynaecologic department, not the Obstetric, and are attended by a doctor, not a midwife. 
For later years, the electronic medical record systems in the Gynaecologic departments are 
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not compatible with the report form to the MBRN, and require hand-written forms instead.
From 2006, induced abortions were not reported to the regular MBRN, but to the separate 
Termination of Pregnancy Registry. Late terminations (gestDWLRQDO ZHHN  have been
reported since 1999. The underreporting makes it impossible to explore whether
spontaneous and induced abortions are more common among female cancer survivors than 
the general population, and for the recent years, whether congenital anomalies are detected 
in early pregnancy and have led to terminations to a higher degree among cancer survivors 
than controls. Similarly, the possible differences in registration make it necessary to define 
stillbirth as from gestational week 22.169
Confounding 
A confounder is a variable which is associated with both the outcome and the exposure, 
without being a consequence of the exposure. To be a confounding factor, it must have an 
effect and be imbalanced between the groups in order to be compared. Confounding factors 
either create a spurious association or mask a real association between the exposure and the 
outcome. To prevent confounding, randomisation, restriction, or matching are common 
procedures. Randomisation is only possible in experiments. Restriction means choosing
subjects for the study who have the same or nearly the same value for a variable that might 
be a confounder (solved by analysing males and females separately, for instance). In 
epidemiologic studies, the common procedure for controlling for confounding adequately is 
to use stratification or adjustments.166
Calendar time, age, extent of disease, parity, and socioeconomic status were the known 
potential confounders accounted for in the analyses. In study I, we stratified by age, using 
randomly drawn controls matched by gender and date of birth, since age is closely related to 
the possibility of having a future pregnancy. For the study of pregnancy-associated cancer 
and cause-specific survival, educational level was not obtained, which could be looked upon 
as an unmeasured confounder. For the study about birth outcome (II), we adjusted both for 
maternal age (at birth) and for calendar period. There have been changes during the study 
period regarding several of the confounding factors. Increase in maternal age at first birth, 
introduction of ultrasound during pregnancy, changes in obstetrical practices, and 
attainment of higher educational level are all factors which influence the risk of adverse 
birth outcomes.
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With our stratification on parity in paper II, it might be argued that comparison with other 
studies is more difficult. Most studies on birth outcomes after cancer have not stratified on 
parity, some compare all pregnancies after cancer, and others make adjustments for birth 
order.23;74-76 Still, parity effects are seldom dealt with in studies exploring outcomes for 
offspring, but might strongly influence the results with dilution or overestimation effects of 
cancer on pregnancy outcome. 
Unmeasured confounders included maternal smoking history. Smoking habits have been
registered in the MBRN since 1999, if the woman gives her consent to such registration, 
unlike most other variables. It is reported that the proportion of daily smoking pregnant 
women at the end of pregnancy was 34% in the lowest level of education, 16% in the 
intermediate level and only 5% in the highest level of education for the period 1999-2004.170
There has been substantial variation during the study period of the proportion of daily 
smoking pregnant women, and for recent years the number has declined further.27
Residual confounding 
Residual confounding remains after adjustments for all known confounding factors. With 
the imperfect categorisation of variables, like treatment or stage, given in very coarse terms, 
the outcome estimate might be influenced by residual confounding. An example is breast 
cancer diagnosed during the lactation period, in paper III, where HR declines from 3.44 to 
1.95 going from uni- to multivariate analyses. 
Precision and lack of random errors 
Even if the whole material is nationwide, sub-analyses have smaller numbers and few 
events. We have used 95% confidence intervals, meaning that there is a 5% possibility that 
the observed association is due to chance. The broadness of the interval reflects the 
precision. 
If a study incorrectly rejects a null hypothesis, meaning that analyses show that a difference 
does exist when it does not, this is called a type I error. For instance, this might be the case 
in paper II, where sub-analyses for different cancer types with congenital anomalies as the 
outcome, resulted in significantly increased risk among offspring of primiparous breast and 
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nulliparous ovarian cancer survivors. The events were few: 4/43 and 4/44, respectively. 
Additionally, the increased risks were only found for one of the parity groups for each 
cancer type, not both.  
If there is no apparent difference among the groups studied, indicated by a p-value > 0.05, 
despite the existence of a real difference, it is called a type II error. If a test is 
underpowered, the type II error is large, resulting in difficulty in detecting a real effect, if 
the effect indeed exists. This might for instance have been true for other cancer types with 
regard to congenital anomalies, where the number of events, and thus, the power of the test, 
was low.165
Advantages and limitations of registry-based materials 
We have conducted three population-based studies, including all cancer patients in Norway 
with an age of 16-45/49 at diagnosis over a period for more than 35 years. The registry-
based data are virtually complete, because of mandatory reporting, negligible numbers lost 
to follow-up since people in Norway have a low tendency to emigrate, and the registries 
having been run for decades. Moreover, the linkage is of high quality due to the unique 
personal identification number. Unselected materials like nationwide materials, like ours,
are necessary for incidence estimation. 
Limiting factors with registry-based studies are the lack of detailed cancer treatment 
information, lack of prognostic factors, and lack of medical information on the offspring 
after the first days of life. Since treatment is notified only in broad terms, and restricted to 
the first four months after diagnosis, no treatment variables are used in this thesis, since we 
doubt that the whole treatment period is reflected, especially for patients who have received 
multimodal treatment. Instead, general national treatment routines are used (table 1, paper I)
to stratify by treatment-related changes. 
Hospital-based studies are useful supplements to register-based studies since they often 
provide more detail regarding treatment and prognostic factors, but have short-comings 
regarding selection, and cannot provide reliable incidence rates. Paper I and II, in 
comparison with similar studies conducted among patients from the Norwegian Radium 
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Hospital, reveal considerable differences between the studies regarding patient population, 
explaining, at least to some degree, the different results for some of the analyses.1;2;66;160
With registry-based materials, there is uncertainty or underreporting of certain variables, 
and other variables have been introduced more recently. Several examples are listed above;
additionally, gestational length might be misclassified for some individuals since the date of 
last menstruation might be uncertain, and the reasons for caesarean section are 
underreported. Prognostic factors like serum tumour markers, hormone receptor status, 
tumour depth, and detailed stage or grading information are not routinely registered in 
cancer registers. Some of the above-mentioned factors are registered during the most recent 
years, but could in our study only be considered in specific subgroup analyses. This is a 
limitation of ours and similar studies, which can only be solved by adding information from 
the medical records for each patient, which would have been time-consuming and costly. 
There is no doubt that the reliability would have been increased further, if all of the accepted 
prognostic risk factors could have been adjusted for. 
With reproduction as the main outcome, there are several limitations in our material. We do 
not have knowledge about partner status at diagnosis, or pre- and post-diagnostic wishes for 
children, nor do we know anything about failed attempts to get pregnant after cancer. Such 
information would have been available only if a survey was added to the registry-based 
material, or partly, with information from the individual’s medical records. 
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General discussion of the results 
Are pregnancy rates after cancer lower than in the general population, and are 
there differences regarding cancer type and treatment? 
We found a reduction in pregnancy rates after cancer of 25% among male cancer survivors 
and 40% among female survivors compared to their controls. Separated by cancer types, 
only malignant melanoma and thyroid cancer survivors did not differ from their controls. 
Other authors reports similar findings.2;23;24 A recent paper based on a Swedish cohort had 
similar findings; female cancer survivors were 27% less likely to give birth after cancer, 
compared to the cancer-free background population at a similar age.171 Somatic changes 
related to the cancer are most probably the primary explanation for these observations, with 
treatment leading to sub- or infertility as the main reason. Gonadotoxic chemotherapy is 
probably the major explanation why survivors of leukaemia, partly HL, breast, and ovarian 
cancer have low associated pregnancy rates. 
Reasons other than infertility might also influence the pregnancy rates after cancer. 
Several smaller studies with questionnaires have been performed, which cover information 
of marital status at diagnosis and desire for future children. The wish to have a biological
child is deeply rooted, and it has been shown that the majority of individuals still want 
children even after a serious illness like cancer.28;172 However, survivors of testicular and 
cervical cancer are shown to face higher risks of splitting up with their partners after
cancer.26 Psychosocial and socioeconomic factors cannot be excluded with regard to 
parenthood after cancer, even though we could not adjust for them. A part of these 
psychosocial concerns, which might be limiting post-cancer parenthood, may be the fear of 
recurrence or fear of transferring cancer or anomalies to potential offspring. Furthermore,
infertility or unmet desires for future children are associated with decreased quality of life 
and psychological distress, both among cancer survivors and the general population.173
Do male cancer survivors have higher fertility rates than female survivors? 
The results point to the gender difference, with a higher probability for male than female 
survivors to have children after cancer: HR=0.74 (95% CI 0.71-0.78) and HR=0.61 (95% CI 
0.58-0.64), respectively. Regarding age at diagnosis, we found that also the youngest age-
group, 16-25 years, had quite similar results (HR = 0.70 (95% CI 0.65-0.75) and HR = 0.67 
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(95% CI 0.63-0.73) for males and females, respectively). One would expect that a cancer 
diagnosis before the age of 25 in females would be protective with regards to the ovarian 
capacity, and the results are slightly better for women aged 25 years or less at diagnosis. 
There might also be other factors like type of cancer and treatment that influence the post-
cancer pregnancy rates. 
Regarding fertility-preserving efforts, males have been offered semen cryopreservation for 
decades, and the vast majority are able to do this because of impaired general condition at 
the time of diagnosis. Recovery is seen in sperm samples, but for some males, the time to 
recovery or to when satisfactory sperm cell account and motility is seen will differ.10;174 In 
cases of post-treatment subfertility, ICSI can be performed, even if the sperm cell number is 
low.
For females, the situation is far more difficult, but experimental initiatives like ovarian 
tissue cryopreservation seem promising, especially for young females. The crucial point in 
many cases is to give proper counselling, since most methods for fertility-preservation 
require a period of hormonal stimulation for females, except for cryopreservation of ovarian 
tissue. Fertility should be discussed with newly diagnosed cancer patients on equal terms 
with other side effects that might occur as a result of the planned treatment. The literature 
shows that fertility issues are discussed more often with male than female cancer patients 
(males given information 14 times more frequent than females), both the risk of sub- or 
infertility, and possible fertility-preserving efforts.172 Historically, counselling of female 
patients about subsequent pregnancies might have differed throughout the period studied, 
with more reservations earlier, especially for cancer types regarded as hormone-sensitive. 
The attitude towards initiating a pregnancy when having a history of cancer might also be 
different, both between genders, but also at an individual level.
Costs of infertility treatment are part of the tax-funded health care system in Norway and 
other Nordic countries, with three attempts usually covered for each couple, and a sum of 
about 2000 euro for one’s own account. The majority of cancer survivors will retain or 
regain their fertility after treatment. The difficult part is the individual vulnerability for the 
treatment, and for females the biological time of decrease in fertility and menopause which 
is not known. The risk of POF cannot be detected pre-treatment today, even if AMH is 
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considered a promising parameter. A recent study revealed a pre-treatment measure of 
AMH as a predictive measure of post-treatment fertility, with higher precision than age at 
treatment.175;176
Have fertility-preserving efforts resulted in increased fertility-rates after cancer 
for selected cancer types? 
For ovarian cancer stage I, a significant improvement was seen during the study period 
(HR = 0.19 [95% CI 0.11-0.32] to HR = 0.67 [95% CI 0.49-0.90]). Testicular cancer 
underwent a significant change from the 1980s to the 1990s, where RPLND was performed 
bilaterally in the first period, and unilaterally in the second: HR = 0.51 (95% 0.45-0.59) to 
HR = 0.76 (95% CI 0.70-0.83), respectively. For males with HL, a tendency of higher rates 
of children after cancer was seen after ABVD was introduced. Further details in treatment 
changes are explained in the background chapter and in paper II.
For cervical cancer stage I, we did not see such an expected increase during the period;
however, the fertility-preserving surgical methods have been applied since the 1970s, which 
practically cover the whole study period.
Are congenital anomaly rates in offspring born to cancer survivors equal to those 
in the general population? 
The vast majority of cancer survivors who had subsequent children gave birth to healthy 
infants. For all cancer types combined, no increased risk of congenital anomalies was found. 
The risk of adverse pregnancy outcome, especially foetal death and congenital anomalies, is 
a major concern for cancer survivors. In our population-based material, the number of 
outcomes is still small for many subgroups, calling for careful interpretation. There are 
some other population-based materials published from the other Nordic countries, with 
different results.2;177 This might be due to differences in design. It emphasises the necessity 
of even larger materials to answer these questions. Several studies are performed on
childhood cancer survivors, not showing any increased risks of congenital anomalies in the 
offspring.178-180
Ståhl et al. have recently published a study based on a population-based material including 
all males in Sweden and Denmark with a history of cancer and fathering a child afterwards, 
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finding that the risk of congenital anomalies in the offspring was increased after all cancer 
types seen together. They analysed all children born after cancer, regardless of parity. The 
sites for the cancer types associated with higher risks of anomalies were skin, eye, and 
central nervous system, which probably include a large proportion of survivors from 
malignant melanoma. The offspring of survivors of testicular cancer or haematological 
malignancies did not differ from the cancer-free populations’ offspring.177 Compared with 
the findings of the study by Magelssen et al., regarding altered risk of anomalies among the 
offspring, based on a hospital-based material from the Norwegian Radium Hospital, the 
cancer types differ. Magelssen’s study reports testicular cancer and malignant lymphoma as 
the most frequent cancer types for males who fathered a child with an anomaly.2 The 
difference between the findings from these two studies including male cancer patients could 
probably be caused by chance findings, since congenital anomalies are rare events. 
At least, there is little evidence for concluding that specific cancer types impose higher risks 
of anomalies among subsequently born offspring. 
As described in the results, there were considerably larger differences between the materials 
used for the studies by ourselves and Magelssen, with regard to the number of malignant 
melanoma patients. The hospital-based study found that male survivors had an increased 
risk of a baby with a congenital anomaly, while we did not find that; this could reflect the 
selection of patients referred to the Norwegian Radium Hospital, with a higher number of 
more severe cases needing more treatment. 
Are adverse pregnancy outcomes like perinatal death, preterm birth and low birth 
weight more frequently seen in infants delivered by female cancer survivors than 
in offspring of females without cancer? 
Increased risks of preterm birth and LBW at term were found among offspring of female 
survivors compared to their controls, and more often among primiparous than nulliparous 
survivors. However, other authors have reported contradictory results regarding perinatal 
death, preterm birth, and LBW after female cancer.2;23;74-78 Higher frequency of perinatal 
death among cancer survivors was demonstrated recently to be associated with the time 
since cancer, which is comparable with our findings with higher risks if the pregnancy was 
initiated during the first two years after the diagnosis of malignancy.181
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Our findings of different risk patterns with higher risk estimates of preterm birth, LBW and 
even perinatal death for primiparous than for nulliparous female survivors have not been 
previously reported, to the best of my knowledge. It is unclear what the mechanisms are. 
The arguments of having a pregnancy after cancer might be different for those two groups. 
Since primiparous female survivors have already experienced pregnancy, it might be easier 
to undergo a second one, even after a serious disease like cancer. Also, the threshold may be 
equivalently higher for nulliparous individuals, so only the healthiest ones will choose to get 
pregnant. There might also be age-dependent effects that influence the primiparous group 
more than the nulliparous group. This could probably involve a similar mechanism as seen 
for the development of POF effects mediated from the cancer treatment increasing the 
biological age, at least in some organs.
We found a higher incidence of pre-eclampsia among primiparous cancer survivors than 
among primiparous females without cancer. This might be due to the toxic effects of the 
cancer treatment, especially chemotherapy, inducing oxidative stress. A similar finding has 
been reported recently in a case report with a pregnant woman treated with chemotherapy 
already from the first trimester for breast cancer. She was gravida 4, para 1, and developed 
severe pre-eclampsia, leading to acute caesarean section in gestational week 36.182 There 
has been no other report of such findings, to the best of my knowledge. 
The usual increase in birth weight from sibling one to sibling two is about 140 grams.183
Magelssen et al. found a decrease in birth weight for the second sibling when the mother 
had cancer before the second pregnancy, and we found a similar difference for the 
subpopulation of female cancer survivors without malignant melanoma, with only a slight 
weight increase from the first to second baby (37 grams compared to 146 grams increase 
from first to second baby among the controls).184
What is the incidence of pregnancy-associated cancer? 
The incidence of cancer during pregnancy is most often described as 1:1000.80;81 We found 
an incidence of about 1:4000 for the whole study period if only the pregnancy period was
included, and 1:2000 if the first six months postpartum were included. This might reflect 
differences in different populations, and different definitions of “during pregnancy” as some 
authors include the first postpartum year as well, especially for breast cancer. It also reflects 
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that such numbers are based on few large materials, and reflect a relatively rare situation, 
therefore requiring the tag “estimated incidence”, due to random variation. 
Incidence should be based on population-based materials, and might be wrongly determined 
if materials are hospital-based or selected in other ways. Examples are the frequently 
published statement that breast cancer (or eventual cervical cancer) is the most common 
cancer type diagnosed during pregnancy, and the conflicting results regarding pregnancy 
outcome in offspring of cancer survivors. Breast cancer is the most common cancer type in 
the age group 16-45 years, but not the most frequent diagnosis during pregnancy, lactation 
or in the group of females with a subsequent pregnancy, since other cancer types like 
cervical cancer, brain tumours, and lymphoid and haematopoetic malignancies are more 
common until the mid-thirties.3 We found that malignant melanoma is by far the most 
frequent cancer type both during pregnancy and lactation, with cervical cancer being the 
second most common, and breast cancer third. Similar incidence rates have been reported by 
others.98
Incidence is a matter of external validity, since generalisation of the results also depends on 
ethnicity and different risk patterns for developing cancer. With the knowledge of high 
incidence of cutaneous malignant melanoma in Norway and fair-skinned people living in 
Northern-Europe, the USA, Canada, Australia and New Zealand, the distribution of cancer 
types might differ among various skin types. Further, the median age at diagnosis is higher 
for breast cancer than for malignant melanoma. Breast cancer has a later onset than 
malignant melanoma (median age at diagnosis was 29 and 34 years old, respectively). This 
influences the numbers of females diagnosed during pregnancy, and even those who have a 
subsequent pregnancy. Since many of the papers only focus on one cancer type during 
pregnancy, and few studies are population-based, statements such as “breast cancer is the 
most common cancer during pregnancy” have come into being. 
Is survival for females diagnosed with cancer during pregnancy poorer than for 
non-pregnant females, especially for selected cancer types?  
Breast cancer diagnosed during pregnancy has been postulated to implicate poorer 
prognosis, historically based on a hormone hypothesis, meaning that tumour cells are 
promoted by higher levels of oestrogen during pregnancy. Another crucial point is the 
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treatment; postponement of initiation and reduction of aggressiveness have probably been 
more common than the opposite. A third reason why cancer diagnosed during or shortly 
after pregnancy seems to be associated with adverse outcome, is the transient increased risk 
of breast cancer risk after a pregnancy, as this period is probably longer with higher 
maternal age.93;101;102;185 A fourth (or maybe part of the third) explanation for the poorer 
prognosis of PABC, is the hypothesis about involution, a tumour promoting tissue 
microenvironment following pregnancy and lactation. After the cessation of breastfeeding, 
there is an involution of the breast, meaning a regression of the mammary gland in an 
inflammatory-like process, with increased immune cell influx and breakdown of the stroma 
surrounding the glands and the ducts. The changes occurring are postulated to enhance 
tumour growth and the growth of metastases.93;94 A Norwegian study reported a high 
proportion of poorly differentiated tumours, partly explained by young age, in women with 
a recent childbirth.186
The hormonal hypothesis, for breast cancer in particular, is presumably not the main reason 
for the adverse prognosis for those diagnosed during pregnancy. Since several studies reveal 
similar prognosis compared to the non-pregnant population, while stage is properly adjusted 
for, it is time to question this hypothesis. Similarly, for malignant melanoma, reassuring 
results were found in our study and two other large studies.115;116
Most malignancies seem to be diagnosed at a later stage when they occur during pregnancy 
and even post-partum. The young age of the patients and the gestational symptoms might 
mislead physicians to interpret the symptoms as caused by the pregnancy or lactation, 
instead of by a malignancy. Several studies regarding gestational malignant melanoma and 
breast cancer reveal the more advanced stage at diagnosis among the pregnant patients 
compared to the non-pregnant.92;93;96;109;110;187 This emphasises the advice to always biopsy a 
suspect mole, or consider diagnostic procedures as ultrasound and cytology of a suspect 
tumour in the breast of a pregnant or lactating woman. Mammography can be safely done 
post-partum, but interpretation might be more difficult for all imaging diagnostic procedures 
for women who are pregnant or lactating at examination. 
In a recent paper by Johansson et al., a Swedish material was investigated, and they stated
increased mortality in women with breast cancer diagnosed during or shortly after 
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pregnancy. A crucial limitation of that study was the lack of adjustment for extent of 
disease.188 In our analyses, extent of disease was the most important factor for the 
covariates, as shown in Table 4. The same group have more recently published a paper 
where stage at diagnosis is adjusted for, but with a smaller number of patients. They then 
reported a mortality of HR = 1.27 (95% CI 0.88-1.83) when adjusting for stage, age, and 
calendar year.189
Table 4 
Breast cancer diagnosed during pregnancy or lactation period and survival* 
Dx during pregnancy
HR (95% CI)
Dx during lactation
HR (95% CI)
Unadjusted 1.76 (1.20-2.56) 3.46 (2.43-4.93)
Adjusted for age at diagnosis 1.41 (0.95-2.08) 2.67 (1.87-3.81)
Adjusted for calendar period 1.83 (1.24-2.69) 3.47 (2.44-4.94)
Adjusted for extent of disease 1.29 (0.88-1.90) 2.40 (1.68-3.42)
Adjusted for age, period, and extent 1.23 (0.83-1.81) 1.95 (1.36-2.78)
*The table contents the hazard rates for cause-specific survival of breast cancer, if diagnosed during 
pregnancy or lactation, compared to those who not where pregnant or diagnosed during the first 6 
months post-partum. Estimates for each one of the covariates are given, and at last, the completely 
adjusted HRs. The table is extracted from the background statistics for the paper “Cause-specific 
survival for women diagnosed with cancer during pregnancy or lactation: A registry-based cohort 
study”(paper III).164 
However, Johansson et al. have an interesting story told by the numbers themselves: They 
found 107 patients diagnosed with breast cancer during pregnancy (defined as a 9 month 
long period prior to birth), 140 diagnosed during the first 6 months post-partum, 281 during 
7-12 months after birth, 296 during 13-18 months post-partum, and finally 286 women 
diagnosed during 19-24 months after birth.188 The high increase in incidence from the last 
part of the first year post-partum compared to the lower numbers during pregnancy and the 
first 6 months post-partum might be explained by a delay in diagnosis. This finding might 
also be regarded an effect of transient increased risk of breast cancer after a pregnancy (this 
might be potentiated by the selection of pregnancies; if there were more than one pregnancy 
during the observation period, the second one was chosen), and finally maybe by the 
involution hypothesis.
Our approach to dividing pregnant and lactating cancer patients takes into account the 
treatment differences that might influence an aggregated group (gestational cancer). Cancer 
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diagnosed during pregnancy might be differently handled than tumours diagnosed during 
lactation, taking the foetus into account. Authors have argued that subgroups, like those
presented here, are of no use, since the cancer most likely started to grow long before the 
pregnancy was initiated.94 For some of the cancer types, especially breast cancer, which we 
know has a dualistic risk pattern after pregnancy, it can be useful to include longer time 
intervals. For all cancer types seen together, I believe it still can be useful to analyse
pregnant and lactating patients separately, to take eventual differences in diagnostics and 
treatment into account, even if most malignancies originated before the pregnancy or 
lactation period started. 
History has revealed how counselling can seriously influence a patient’s life. Examples are 
consideration of the necessity of castration of pre-menopausal women diagnosed with breast 
cancer, which not only eliminates the possibility of becoming pregnant, but also introduces
other possible adverse side effects. Further, advice about the termination of concurrent or 
subsequent pregnancies for women diagnosed with breast cancer and even other cancer 
types like malignant melanoma has been given, which we today know is unnecessary. 
Historical data, at least for breast cancer and malignant melanoma, evidenced mainly by 
case-reports published from the 1950s and onwards, did not leave much hope for the 
prognosis of those diagnosed during pregnancy.84;103 It is easy to understand that pregnant 
patients with poor outcomes made deep impressions on the clinicians, but with today’s 
knowledge, several decisions were taken based on weak evidence. We will never know how 
much a delay in treatment or lack of treatment influenced this group, compared to the non-
pregnant proportion of the cancer patients of similar age.86-88;103
Today, thanks to reports from dedicated physicians and the collection of data, we know 
more about cancer treatment during pregnancy, and what harms the foetus and what most 
likely does not.72 Guidelines regarding diagnostics and treatment are to be published, like,
for instance, the French recommendations for cervical and ovarian cancer diagnosed during 
pregnancy and recommendations based on consensus meetings.8;85;190-192 Proper counselling 
and decision-making needs to be evidence-based as far as possible. Still, it seems that the 
new knowledge has not yet been fully incorporated, and that clinicians do not dare give 
cancer treatment during pregnancy: A recent survey revealed that current treatment is not in 
line with recent evidence, with several more terminations and delays of maternal treatment 
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than necessary. University clinics had the best outcome in this European survey, compared 
to non-academic hospitals.193
Another fear of cancer during pregnancy is the risk of the transmission of malignant cells to 
the placenta and to the foetus. As described earlier, it is extremely rare that placental 
invasion is detected, and even rarer that the foetus is involved. For all females who are 
diagnosed with cancer during pregnancy, the placenta should be properly examined, with 
macroscopic and histopathological methods, including cytology of maternal and umbilical 
cord blood. The infants should obviously be thoroughly examined as newborns, with regular 
follow-ups during of the first years of life. In a recent review, a total of 87 cases have been
described during the 20th century, with 19 cases involving the foetus. Malignant melanoma 
(31%) and breast cancer (17%) are the two most common cancer types with placenta and/or 
foetal metastases, 194 followed by NHL and leukemia.82;137
Do female survivors with subsequent pregnancies have poorer survival than those 
not becoming pregnant after cancer? 
We did not find that women with pregnancies after cancer had any inferior survival in our 
study.164 Few contemporary studies report adverse survival for females becoming pregnant 
after cancer. The exception is those becoming pregnant very shortly after cancer.67
Also, a recent study based on Swedish and Singaporean material has shown lower mortality 
rates for breast cancer survivors with subsequent pregnancies than for breast cancer 
survivors without pregnancies after cancer; however, in comparison with women in from the 
background population at similar age, cancer survivors with subsequent pregnancies had 
higher mortality rates.195
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SUMMARY AND CONCLUSIONS 
Paper I 
Cancer survivors of both genders have significantly lower pregnancy rates after diagnosis 
than controls in the same age group. For all cancer types seen together, the pregnancy rates 
for males were reduced by 26% and for females by 39%. However, a diagnosis of malignant 
melanoma or thyroid cancer did not affect the pregnancy rates. Fertility-preserving anti-
cancer treatment has showed a positive effect for females with ovarian cancer and males 
with testicular cancer and HL, since their pregnancy rates increased during the study period. 
Paper II 
We did not find any increased risk of adverse birth outcome for the male survivors’ 
offspring; in particular, no increased risk of congenital anomalies was seen. Risk of preterm 
birth after cancer was increased by 90% among primiparous and by 30% among nulliparous 
female cancer survivors. For the offspring of primiparous female survivors, an increased 
risk of LBW and perinatal death emerged. Higher parity might be associated with higher 
risks of adverse birth outcomes after cancer. 
Paper III 
The incidence of pregnancy-associated cancer was 1:2000. Malignant melanoma, cervical 
cancer and breast cancer were the most frequent cancer types during pregnancy or lactation, 
in that order. Cancer diagnosed during pregnancy was not associated with an increased risk 
of cause-specific death for all cancer types combined. Malignant melanoma diagnosed 
during pregnancy represented an exception, with a borderline increased risk. Cancer
diagnosed during the lactation period did not increase cause-specific death, except for 
females diagnosed with breast or ovarian cancer. Patients with malignant melanoma or those 
with breast or ovarian cancer could all be at risk of delayed diagnosis, as the symptoms 
could be interpreted as pregnancy or post-natal conditions. None of the cancer types were 
linked to worse survival for those who had subsequent pregnancies. 
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FUTURE PERSPECTIVES 
For all of the topics assessed in this thesis, nationwide materials like ours are still small 
when the numbers of events are rare or the subgroups are small, even though the study 
period ranged over several decades. An expanded cohort, for example a Nordic material 
based on information from cancer registries and birth registries, would decrease the 
possibility of chance findings and increase the reliability. In such an expanded material, 
childhood cancer might also be included, enabling the assessment of differences among age-
groups and different cancer types, regarding fertility after cancer and birth outcomes for the 
offspring. To further strengthen the results, information from medical records like 
prognostic factors and detailed treatment information would be desirable, either through 
requests for such information to the hospitals, or more efficiently, through already 
established quality registers. There are several areas where further research is needed:
Fertility and cancer: 
x Provision of personalised cancer treatment when possible based on fertility potential 
and wishes at the time of cancer diagnosis, taking the chance of cancer cure into 
account. Proper information about fertility potential and methods to preserve it 
should be given at diagnosis.
x Guidelines should be created for relevant subgroups with information about 
reproductive health after cancer treatment, including estimations of the possibility of 
post-cancer parenthood and/or possible techniques to preserve fertility. In particular, 
there is a need for putting experimental techniques for fertility-preserving methods 
for women into effect.
x The role of AMH needs to be further explored; is a pre-treatment level predictive 
enough, together with age, to counsel women about the need for fertility-preserving 
efforts like ovarian tissue cryopreservation or not? Is AMH reliable enough post-
treatment to predict ovarian functioning and estimate menopausal age?
Birth outcomes of cancer survivors: 
x Further research is required into the effects of parity, since our study revealed higher 
risks of adverse birth outcome for primiparous compared to nulliparous females who 
became pregnant after cancer treatment. 
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x Assessing birth outcome after cancer (congenital anomalies and perinatal death) in 
an expanded cohort, for example using a Nordic material, because of contradictory 
findings.
x Perform long-lasting follow-up studies of offspring who have been exposed to 
cancer treatment in utero, maybe based on international registration.
Cancer during pregnancy:  
x Develop guidelines for multidisciplinary cancer care of women confronted by a 
malignant diagnosis during pregnancy in order to offer optimal diagnostics and 
treatment with a maximal chance of cure of the mother and minimal risk for the
infant in utero. Establish a (national) referral system in order to centralise specific 
expertise, for the best care of the mother and child.
x Develop guidelines for the follow-up of women pregnant subsequent to a cancer 
diagnosis.
x Further studies on the survival of females diagnosed with cancer associated with
pregnancy need to explore prognostic factors, e.g. to determine whether HER-2
negative and positive breast cancer tumours during pregnancy have different 
outcomes, if malignant melanoma site, tumour thickness, or certain skin types have 
poorer prognosis than others, and if there is a difference in prognosis if the 
malignancy is diagnosed during pregnancy or shortly thereafter.
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Errata 
In paper III, table 2, the correct number of lymphoma and laeukemia patients pregnant after 
cancer that died in the group OAS 60; i.e. overall survival at age 60, should be 33, and not 
272, as listed.
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